메뉴 건너뛰기




Volumn 29, Issue 4, 2016, Pages 564-616

Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ACETYL COENZYME A CARBOXYLASE INHIBITOR; BLOOD CLOTTING FACTOR 10A INHIBITOR; CANNABINOID 2 RECEPTOR AGONIST; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; ELEMENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; IMATINIB; MARAVIROC; METHYLTRANSFERASE INHIBITOR; MONTIRELIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NONSTRUCTURAL PROTEIN 5A INHIBITOR; OXYTOCIN ANTAGONIST; PROTEIN N MYRISTOYLTRANSFERASE INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; SELECTIVE ANDROGEN RECEPTOR MODULATOR; TAXANE DERIVATIVE; DRUG; LIGAND;

EID: 84964692636     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/acs.chemrestox.6b00043     Document Type: Review
Times cited : (155)

References (335)
  • 1
    • 84964602086 scopus 로고    scopus 로고
    • The practice of medicinal chemistry and its contributions to therapy
    • Meanwell, N. A., Olson, R. E., and Cheng, P. T. (2015) The practice of medicinal chemistry and its contributions to therapy 2015 Med. Chem. Rev. 50, 359-393
    • (2015) 2015 Med. Chem. Rev. , vol.50 , pp. 359-393
    • Meanwell, N.A.1    Olson, R.E.2    Cheng, P.T.3
  • 2
    • 4344673155 scopus 로고    scopus 로고
    • Sources of U.S. longevity increase, 1960-2001
    • Lichtenberg, F. R. (2004) Sources of U.S. longevity increase, 1960-2001 Quart. Rev. Economics Finance 44, 369-389 10.1016/j.qref.2004.05.005
    • (2004) Quart. Rev. Economics Finance , vol.44 , pp. 369-389
    • Lichtenberg, F.R.1
  • 3
    • 0346620161 scopus 로고    scopus 로고
    • The effect of new drug approvals on HIV mortality in the US, 1987-1998
    • Lichtenberg, F. R. (2003) The effect of new drug approvals on HIV mortality in the US, 1987-1998 Economics Human Biol. 1, 259-266 10.1016/S1570-677X(02)00031-X
    • (2003) Economics Human Biol. , vol.1 , pp. 259-266
    • Lichtenberg, F.R.1
  • 4
    • 61449189645 scopus 로고    scopus 로고
    • Anti-HIV drugs: 25 Compounds approved within 25 years after the discovery of HIV
    • De Clercq, E. (2009) Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV Int. J. Antimicrob. Agents 33, 307-320 10.1016/j.ijantimicag.2008.10.010
    • (2009) Int. J. Antimicrob. Agents , vol.33 , pp. 307-320
    • De Clercq, E.1
  • 5
    • 77249134151 scopus 로고    scopus 로고
    • Twenty-six years of anti-HIV drug discovery: Where do we stand and where do we go?
    • Mehellou, Y. and De Clercq, E. (2010) Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? J. Med. Chem. 53, 521-538 10.1021/jm900492g
    • (2010) J. Med. Chem. , vol.53 , pp. 521-538
    • Mehellou, Y.1    De Clercq, E.2
  • 6
    • 73549103358 scopus 로고    scopus 로고
    • The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic
    • Broder, S. (2010) The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic Antiviral Res. 85, 1-18 10.1016/j.antiviral.2009.10.002
    • (2010) Antiviral Res. , vol.85 , pp. 1-18
    • Broder, S.1
  • 7
    • 84898990930 scopus 로고    scopus 로고
    • New hepatitis C therapies: The toolbox, strategies, and challenges
    • Pawlotsky, J.-M. (2014) New hepatitis C therapies: the toolbox, strategies, and challenges Gastroenterology 146, 1176-1192 10.1053/j.gastro.2014.03.003
    • (2014) Gastroenterology , vol.146 , pp. 1176-1192
    • Pawlotsky, J.-M.1
  • 8
    • 84934823081 scopus 로고    scopus 로고
    • From non-A, non-B hepatitis to hepatitis C virus cure
    • Pawlotsky, J.-M., Feld, J. J., Zeuzem, S., and Hoofnagle, J. H. (2015) From non-A, non-B hepatitis to hepatitis C virus cure J. Hepatol. 62, S87-S99 10.1016/j.jhep.2015.02.006
    • (2015) J. Hepatol. , vol.62 , pp. S87-S99
    • Pawlotsky, J.-M.1    Feld, J.J.2    Zeuzem, S.3    Hoofnagle, J.H.4
  • 9
    • 4344645978 scopus 로고    scopus 로고
    • Can the pharmaceutical industry reduce attrition rates?
    • Kola, I. and Landis, J. (2004) Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discovery 3, 711-716 10.1038/nrd1470
    • (2004) Nat. Rev. Drug Discovery , vol.3 , pp. 711-716
    • Kola, I.1    Landis, J.2
  • 10
    • 84948472733 scopus 로고    scopus 로고
    • From scientific discovery to cures: Bright stars within a galaxy
    • Williams, R. S., Lotia, S., Holloway, A. K., and Pico, A. R. (2015) From scientific discovery to cures: bright stars within a galaxy Cell 163, 21-23 10.1016/j.cell.2015.09.007
    • (2015) Cell , vol.163 , pp. 21-23
    • Williams, R.S.1    Lotia, S.2    Holloway, A.K.3    Pico, A.R.4
  • 11
    • 84881296154 scopus 로고    scopus 로고
    • Phase II and Phase III attrition rates 2011-2012
    • Arrowsmith, J. and Miller, P. (2013) Phase II and Phase III attrition rates 2011-2012 Nat. Rev. Drug Discovery 12, 569 10.1038/nrd4090
    • (2013) Nat. Rev. Drug Discovery , vol.12 , pp. 569
    • Arrowsmith, J.1    Miller, P.2
  • 14
    • 84924076465 scopus 로고    scopus 로고
    • What does it take to produce a breakthrough drug?
    • Calcoen, D., Elias, L., and Yu, X. (2015) What does it take to produce a breakthrough drug? Nat. Rev. Drug Discovery 14, 161-162 10.1038/nrd4570
    • (2015) Nat. Rev. Drug Discovery , vol.14 , pp. 161-162
    • Calcoen, D.1    Elias, L.2    Yu, X.3
  • 16
    • 81755173447 scopus 로고    scopus 로고
    • An assessment of R&D productivity in the pharmaceutical industry
    • Dimitri, N. (2011) An assessment of R&D productivity in the pharmaceutical industry Trends Pharmacol. Sci. 32, 683-685 10.1016/j.tips.2011.09.005
    • (2011) Trends Pharmacol. Sci. , vol.32 , pp. 683-685
    • Dimitri, N.1
  • 18
    • 84860690620 scopus 로고    scopus 로고
    • Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival
    • Morgan, P., Van Der Graaf, P. H., Arrowsmith, J., Feltner, D. E., Drummond, K. S., Wegner, C. D., and Street, S. D. A. (2012) Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival Drug Discovery Today 17, 419-424 10.1016/j.drudis.2011.12.020
    • (2012) Drug Discovery Today , vol.17 , pp. 419-424
    • Morgan, P.1    Van Der Graaf, P.H.2    Arrowsmith, J.3    Feltner, D.E.4    Drummond, K.S.5    Wegner, C.D.6    Street, S.D.A.7
  • 19
    • 84866739808 scopus 로고    scopus 로고
    • Drug discovery in pharmaceutical industry: Productivity challenges and trends
    • Khanna, I. (2012) Drug discovery in pharmaceutical industry: productivity challenges and trends Drug Discovery Today 17, 1088-1102 10.1016/j.drudis.2012.05.007
    • (2012) Drug Discovery Today , vol.17 , pp. 1088-1102
    • Khanna, I.1
  • 20
    • 84866385163 scopus 로고    scopus 로고
    • Four lessons from global health drug discovery: Medicine for an ailing industry?
    • Elliott, R. L. (2012) Four lessons from global health drug discovery: medicine for an ailing industry? ACS Med. Chem. Lett. 3, 688-690 10.1021/ml3002105
    • (2012) ACS Med. Chem. Lett. , vol.3 , pp. 688-690
    • Elliott, R.L.1
  • 21
    • 84889593989 scopus 로고    scopus 로고
    • Does size matter in R&D productivity? If not, what does?
    • Ringel, M., Tollman, P., Hersch, G., and Schulze, U. (2013) Does size matter in R&D productivity? If not, what does? Nat. Rev. Drug Discovery 12, 901-902 10.1038/nrd4164
    • (2013) Nat. Rev. Drug Discovery , vol.12 , pp. 901-902
    • Ringel, M.1    Tollman, P.2    Hersch, G.3    Schulze, U.4
  • 22
    • 84874732406 scopus 로고    scopus 로고
    • Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift
    • Sams-Dodd, F. (2013) Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift Drug Discovery Today 18, 211-217 10.1016/j.drudis.2012.10.010
    • (2013) Drug Discovery Today , vol.18 , pp. 211-217
    • Sams-Dodd, F.1
  • 24
    • 84897425769 scopus 로고    scopus 로고
    • Preclinical research: Make mouse studies work
    • Perrin, S. (2014) Preclinical research: make mouse studies work Nature 507, 423-425 10.1038/507423a
    • (2014) Nature , vol.507 , pp. 423-425
    • Perrin, S.1
  • 25
    • 84904276702 scopus 로고    scopus 로고
    • Discovery of innovative therapeutics: Today's realities and tomorro's vision. 2. Pharma's challenges and their commitment to innovation
    • Abou-Gharbia, M. and Childers, W. E. (2014) Discovery of innovative therapeutics: today's realities and tomorrow's vision. 2. Pharma's challenges and their commitment to innovation J. Med. Chem. 57, 5525-5553 10.1021/jm401564r
    • (2014) J. Med. Chem. , vol.57 , pp. 5525-5553
    • Abou-Gharbia, M.1    Childers, W.E.2
  • 26
    • 84896398034 scopus 로고    scopus 로고
    • The development speed paradox: Can increasing development speed reduce R&D productivity?
    • Lendrem, D. W. and Lendrem, B. C. (2014) The development speed paradox: can increasing development speed reduce R&D productivity? Drug Discovery Today 19, 209-214 10.1016/j.drudis.2013.09.002
    • (2014) Drug Discovery Today , vol.19 , pp. 209-214
    • Lendrem, D.W.1    Lendrem, B.C.2
  • 27
    • 84893100457 scopus 로고    scopus 로고
    • Improving productivity of modern-day drug discovery
    • Breyer, M. D. (2014) Improving productivity of modern-day drug discovery Expert Opin. Drug Discovery 9, 115-118 10.1517/17460441.2014.870150
    • (2014) Expert Opin. Drug Discovery , vol.9 , pp. 115-118
    • Breyer, M.D.1
  • 29
    • 84940614472 scopus 로고    scopus 로고
    • The current state of drug discovery and what it might take to improve drug discovery outcomes and approval successes
    • Turner, M. J. (2015) The current state of drug discovery and what it might take to improve drug discovery outcomes and approval successes Drug Discovery Today 20, 917-919 10.1016/j.drudis.2015.06.005
    • (2015) Drug Discovery Today , vol.20 , pp. 917-919
    • Turner, M.J.1
  • 31
    • 84927172971 scopus 로고    scopus 로고
    • 2014 FDA drug approvals
    • Mullard, A. (2015) 2014 FDA drug approvals Nat. Rev. Drug Discovery 14, 77-81 10.1038/nrd4545
    • (2015) Nat. Rev. Drug Discovery , vol.14 , pp. 77-81
    • Mullard, A.1
  • 32
    • 84957879028 scopus 로고    scopus 로고
    • Fresh from the biotech pipeline - 2015
    • Mullard, A. (2016) Fresh from the biotech pipeline-2015 Nat. Rev. Drug Discovery 15, 73-76 10.1038/nrd.2016.15
    • (2016) Nat. Rev. Drug Discovery , vol.15 , pp. 73-76
    • Mullard, A.1
  • 33
    • 0037124196 scopus 로고    scopus 로고
    • Drugs, leads, and drug-likeness: An analysis of some recently launched drugs
    • Proudfoot, J. R. (2002) Drugs, leads, and drug-likeness: an analysis of some recently launched drugs Bioorg. Med. Chem. Lett. 12, 1647-1650 10.1016/S0960-894X(02)00244-5
    • (2002) Bioorg. Med. Chem. Lett. , vol.12 , pp. 1647-1650
    • Proudfoot, J.R.1
  • 34
    • 0037468884 scopus 로고    scopus 로고
    • A comparison of physiochemical property profiles of development and marketed oral drugs
    • Wenlock, M. C., Austin, R. P., Barton, P., Davis, A. M., and Leeson, P. D. (2003) A comparison of physiochemical property profiles of development and marketed oral drugs J. Med. Chem. 46, 1250-1256 10.1021/jm021053p
    • (2003) J. Med. Chem. , vol.46 , pp. 1250-1256
    • Wenlock, M.C.1    Austin, R.P.2    Barton, P.3    Davis, A.M.4    Leeson, P.D.5
  • 36
    • 9744232909 scopus 로고    scopus 로고
    • Time-related difference in the physical property profiles of oral drugs
    • Leeson, P. D. and Davis, A. M. (2004) Time-related difference in the physical property profiles of oral drugs J. Med. Chem. 47, 6338-6348 10.1021/jm049717d
    • (2004) J. Med. Chem. , vol.47 , pp. 6338-6348
    • Leeson, P.D.1    Davis, A.M.2
  • 37
    • 16344389354 scopus 로고    scopus 로고
    • The evolution of synthetic oral drug properties
    • Proudfoot, J. R. (2005) The evolution of synthetic oral drug properties Bioorg. Med. Chem. Lett. 15, 1087-1090 10.1016/j.bmcl.2004.12.024
    • (2005) Bioorg. Med. Chem. Lett. , vol.15 , pp. 1087-1090
    • Proudfoot, J.R.1
  • 38
    • 35748934487 scopus 로고    scopus 로고
    • The influence of drug-like concepts on decision making in medicinal chemistry
    • Leeson, P. D. and Springthorpe, B. (2007) The influence of drug-like concepts on decision making in medicinal chemistry Nat. Rev. Drug Discovery 6, 881-890 10.1038/nrd2445
    • (2007) Nat. Rev. Drug Discovery , vol.6 , pp. 881-890
    • Leeson, P.D.1    Springthorpe, B.2
  • 39
    • 80053471789 scopus 로고    scopus 로고
    • The influence of the "organizational factor" on compound quality in drug discovery
    • Leeson, P. D. and St-Galley, S. A. (2011) The influence of the "organizational factor" on compound quality in drug discovery Nat. Rev. Drug Discovery 10, 749-765 10.1038/nrd3552
    • (2011) Nat. Rev. Drug Discovery , vol.10 , pp. 749-765
    • Leeson, P.D.1    St-Galley, S.A.2
  • 40
    • 79851508525 scopus 로고    scopus 로고
    • Impact of ion class and time on oral drug molecular properties
    • Leeson, P. D., St-Galley, S. A., and Wenlock, M. C. (2011) Impact of ion class and time on oral drug molecular properties MedChemComm 2, 91-105 10.1039/C0MD00157K
    • (2011) MedChemComm , vol.2 , pp. 91-105
    • Leeson, P.D.1    St-Galley, S.A.2    Wenlock, M.C.3
  • 41
    • 79955613841 scopus 로고    scopus 로고
    • Molecular obesity, potency and other addictions in drug discovery
    • Hann, M. M. (2011) Molecular obesity, potency and other addictions in drug discovery MedChemComm 2, 349-355 10.1039/c1md00017a
    • (2011) MedChemComm , vol.2 , pp. 349-355
    • Hann, M.M.1
  • 42
    • 52049123291 scopus 로고    scopus 로고
    • Do enthalpy and entropy distinguish first in class from best in class?
    • Freire, E. (2008) Do enthalpy and entropy distinguish first in class from best in class? Drug Discovery Today 13, 869-874 10.1016/j.drudis.2008.07.005
    • (2008) Drug Discovery Today , vol.13 , pp. 869-874
    • Freire, E.1
  • 43
    • 74149083849 scopus 로고    scopus 로고
    • Adding calorimetric data to decision making in lead discovery: A hot tip
    • Ladbury, J. E., Klebe, G., and Freire, E. (2010) Adding calorimetric data to decision making in lead discovery: a hot tip Nat. Rev. Drug Discovery 9, 23-27 10.1038/nrd3054
    • (2010) Nat. Rev. Drug Discovery , vol.9 , pp. 23-27
    • Ladbury, J.E.1    Klebe, G.2    Freire, E.3
  • 44
    • 79959243001 scopus 로고    scopus 로고
    • Thermodynamics of ligand binding and efficiency
    • Reynolds, C. H. and Holloway, M. K. (2011) Thermodynamics of ligand binding and efficiency ACS Med. Chem. Lett. 2, 433-437 10.1021/ml200010k
    • (2011) ACS Med. Chem. Lett. , vol.2 , pp. 433-437
    • Reynolds, C.H.1    Holloway, M.K.2
  • 45
    • 84877768087 scopus 로고    scopus 로고
    • Entropy-enthalpy compensation: Role and ramifications in biomolecular ligand recognition and design
    • Chodera, J. D. and Mobley, D. L. (2013) Entropy-enthalpy compensation: role and ramifications in biomolecular ligand recognition and design Annu. Rev. Biophys. 42, 121-142 10.1146/annurev-biophys-083012-130318
    • (2013) Annu. Rev. Biophys. , vol.42 , pp. 121-142
    • Chodera, J.D.1    Mobley, D.L.2
  • 46
    • 65449179589 scopus 로고    scopus 로고
    • Defining optimum lipophilicity and molecular weight ranges for drug candidates - Molecular weight dependent lower log D limits based on permeability
    • Waring, M. J. (2009) Defining optimum lipophilicity and molecular weight ranges for drug candidates-molecular weight dependent lower log D limits based on permeability Bioorg. Med. Chem. Lett. 19, 2844-2851 10.1016/j.bmcl.2009.03.109
    • (2009) Bioorg. Med. Chem. Lett. , vol.19 , pp. 2844-2851
    • Waring, M.J.1
  • 47
    • 79952171625 scopus 로고    scopus 로고
    • Probing the links between in vitro potency, ADMET and physicochemical parameters
    • Gleeson, M. P., Hersey, A., Montanari, D., and Overington, J. (2011) Probing the links between in vitro potency, ADMET and physicochemical parameters Nat. Rev. Drug Discovery 10, 197-208 10.1038/nrd3367
    • (2011) Nat. Rev. Drug Discovery , vol.10 , pp. 197-208
    • Gleeson, M.P.1    Hersey, A.2    Montanari, D.3    Overington, J.4
  • 48
    • 84909586310 scopus 로고    scopus 로고
    • Oral druggable space beyond the rule of 5: Insights from drugs and clinical candidates
    • Doak, B. C., Over, B., Giordanetto, F., and Kihlberg, J. (2014) Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates Chem. Biol. 21, 1115-1142 10.1016/j.chembiol.2014.08.013
    • (2014) Chem. Biol. , vol.21 , pp. 1115-1142
    • Doak, B.C.1    Over, B.2    Giordanetto, F.3    Kihlberg, J.4
  • 49
    • 84962163302 scopus 로고    scopus 로고
    • How beyond rule of 5 drugs and clinical candidates bind to their targets
    • Doak, B. C., Zheng, J., Dobritzsch, D., and Kihlberg, J. (2015) How beyond rule of 5 drugs and clinical candidates bind to their targets J. Med. Chem. 10.1021/acs.jmedchem.5b01286
    • (2015) J. Med. Chem.
    • Doak, B.C.1    Zheng, J.2    Dobritzsch, D.3    Kihlberg, J.4
  • 50
    • 79851514658 scopus 로고    scopus 로고
    • Lead optimization in the nondrug-like space
    • Zhao, H. (2011) Lead optimization in the nondrug-like space Drug Discovery Today 16, 158-163 10.1016/j.drudis.2010.12.002
    • (2011) Drug Discovery Today , vol.16 , pp. 158-163
    • Zhao, H.1
  • 51
    • 79960153981 scopus 로고    scopus 로고
    • Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space
    • Alex, A., Millan, D. S., Perez, M., Wakenhut, F., and Whitlock, G. (2011) Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space MedChemComm 2, 669-674 10.1039/c1md00093d
    • (2011) MedChemComm , vol.2 , pp. 669-674
    • Alex, A.1    Millan, D.S.2    Perez, M.3    Wakenhut, F.4    Whitlock, G.5
  • 54
    • 33644644973 scopus 로고    scopus 로고
    • Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers
    • Rezai, T., Yu, B., Millhauser, G. L., Jacobson, M. P., and Lokey, R. S. (2006) Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers J. Am. Chem. Soc. 128, 2510-2511 10.1021/ja0563455
    • (2006) J. Am. Chem. Soc. , vol.128 , pp. 2510-2511
    • Rezai, T.1    Yu, B.2    Millhauser, G.L.3    Jacobson, M.P.4    Lokey, R.S.5
  • 56
    • 1942453243 scopus 로고    scopus 로고
    • Ligand efficiency: A useful metric for lead selection
    • Hopkins, A. L., Groom, C. R., and Alex, A. (2004) Ligand efficiency: a useful metric for lead selection Drug Discovery Today 9, 430-431 10.1016/S1359-6446(04)03069-7
    • (2004) Drug Discovery Today , vol.9 , pp. 430-431
    • Hopkins, A.L.1    Groom, C.R.2    Alex, A.3
  • 57
    • 17044403086 scopus 로고    scopus 로고
    • Ligand efficiency indices as guideposts for drug discovery
    • Abad-Zapetero, C. and Metz, J. T. (2005) Ligand efficiency indices as guideposts for drug discovery Drug Discovery Today 10, 464-469 10.1016/S1359-6446(05)03386-6
    • (2005) Drug Discovery Today , vol.10 , pp. 464-469
    • Abad-Zapetero, C.1    Metz, J.T.2
  • 58
    • 34447548576 scopus 로고    scopus 로고
    • Ligand efficiency indices for effective drug discovery
    • Abad-Zapetero, C. (2007) Ligand efficiency indices for effective drug discovery Expert Opin. Drug Discovery 2, 469-488 10.1517/17460441.2.4.469
    • (2007) Expert Opin. Drug Discovery , vol.2 , pp. 469-488
    • Abad-Zapetero, C.1
  • 60
    • 80052974259 scopus 로고    scopus 로고
    • Improving drug candidates by design: A focus on physicochemical properties as a means of improving compound disposition and safety
    • Meanwell, N. A. (2011) Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety Chem. Res. Toxicol. 24, 1420-1456 10.1021/tx200211v
    • (2011) Chem. Res. Toxicol. , vol.24 , pp. 1420-1456
    • Meanwell, N.A.1
  • 62
    • 34447109128 scopus 로고    scopus 로고
    • The role of molecular size in ligand efficiency
    • Reynolds, C. H., Bembenek, S. D., and Tounge, B. A. (2007) The role of molecular size in ligand efficiency Bioorg. Med. Chem. Lett. 17, 4258-4261 10.1016/j.bmcl.2007.05.038
    • (2007) Bioorg. Med. Chem. Lett. , vol.17 , pp. 4258-4261
    • Reynolds, C.H.1    Bembenek, S.D.2    Tounge, B.A.3
  • 63
    • 43049088827 scopus 로고    scopus 로고
    • Ligand binding efficiency: Trends, physical basis, and implications
    • Reynolds, C. H., Tounge, B. A., and Bembenek, S. D. (2008) Ligand binding efficiency: trends, physical basis, and implications J. Med. Chem. 51, 2432-2438 10.1021/jm701255b
    • (2008) J. Med. Chem. , vol.51 , pp. 2432-2438
    • Reynolds, C.H.1    Tounge, B.A.2    Bembenek, S.D.3
  • 64
    • 67650085841 scopus 로고    scopus 로고
    • Simple, size-independent measure of ligand efficiency
    • Nissink, J. W. M. (2009) Simple, size-independent measure of ligand efficiency J. Chem. Inf. Model. 49, 1617-1622 10.1021/ci900094m
    • (2009) J. Chem. Inf. Model. , vol.49 , pp. 1617-1622
    • Nissink, J.W.M.1
  • 65
    • 84892596742 scopus 로고    scopus 로고
    • Improving the plausibility of success with inefficient metrics
    • Shultz, M. D. (2014) Improving the plausibility of success with inefficient metrics ACS Med. Chem. Lett. 5, 2-5 10.1021/ml4004638
    • (2014) ACS Med. Chem. Lett. , vol.5 , pp. 2-5
    • Shultz, M.D.1
  • 66
    • 54449102045 scopus 로고    scopus 로고
    • Group efficiency: A guideline for hits-to-leads chemistry
    • Verdonk, M. L. and Rees, D. C. (2008) Group efficiency: a guideline for hits-to-leads chemistry ChemMedChem 3, 1179-1180 10.1002/cmdc.200800132
    • (2008) ChemMedChem , vol.3 , pp. 1179-1180
    • Verdonk, M.L.1    Rees, D.C.2
  • 67
    • 84885172160 scopus 로고    scopus 로고
    • Setting expectations in molecular optimizations: Strengths and limitations of commonly used composite parameters
    • Shultz, M. D. (2013) Setting expectations in molecular optimizations: strengths and limitations of commonly used composite parameters Bioorg. Med. Chem. Lett. 23, 5980-5991 10.1016/j.bmcl.2013.08.029
    • (2013) Bioorg. Med. Chem. Lett. , vol.23 , pp. 5980-5991
    • Shultz, M.D.1
  • 69
  • 70
    • 84938514887 scopus 로고    scopus 로고
    • Ligand efficiency metrics: Why all the fuss?
    • Reynolds, C. H. (2015) Ligand efficiency metrics: why all the fuss? Future Med. Chem. 7, 1363-1365 10.4155/fmc.15.70
    • (2015) Future Med. Chem. , vol.7 , pp. 1363-1365
    • Reynolds, C.H.1
  • 72
    • 84881369164 scopus 로고    scopus 로고
    • 1-Hydroxypyrazole as a bioisostere of the acetic acid moiety in a series of aldose reductase inhibitors
    • Papastavrou, N., Chatzopoulou, M., Pegklidou, K., and Nicolaou, I. (2013) 1-Hydroxypyrazole as a bioisostere of the acetic acid moiety in a series of aldose reductase inhibitors Bioorg. Med. Chem. 21, 4951-4957 10.1016/j.bmc.2013.06.062
    • (2013) Bioorg. Med. Chem. , vol.21 , pp. 4951-4957
    • Papastavrou, N.1    Chatzopoulou, M.2    Pegklidou, K.3    Nicolaou, I.4
  • 73
    • 77950560159 scopus 로고    scopus 로고
    • An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs
    • Perola, E. (2010) An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs J. Med. Chem. 53, 2986-2997 10.1021/jm100118x
    • (2010) J. Med. Chem. , vol.53 , pp. 2986-2997
    • Perola, E.1
  • 74
    • 77749315417 scopus 로고    scopus 로고
    • Lipophilicity in drug discovery
    • Waring, M. J. (2010) Lipophilicity in drug discovery Expert Opin. Drug Discovery 5, 235-248 10.1517/17460441003605098
    • (2010) Expert Opin. Drug Discovery , vol.5 , pp. 235-248
    • Waring, M.J.1
  • 75
    • 84866879823 scopus 로고    scopus 로고
    • The influence of lipophilicity in drug discovery and design
    • Arnott, J. A. and Planey, S. L. (2012) The influence of lipophilicity in drug discovery and design Expert Opin. Drug Discovery 7, 863-875 10.1517/17460441.2012.714363
    • (2012) Expert Opin. Drug Discovery , vol.7 , pp. 863-875
    • Arnott, J.A.1    Planey, S.L.2
  • 76
    • 84873295517 scopus 로고    scopus 로고
    • Lipophilic efficiency: The most important efficiency metric in medicinal chemistry
    • Freeman-Cook, K. D. (2013) Lipophilic efficiency: the most important efficiency metric in medicinal chemistry Future Med. Chem. 5, 113-115 10.4155/fmc.12.208
    • (2013) Future Med. Chem. , vol.5 , pp. 113-115
    • Freeman-Cook, K.D.1
  • 77
    • 0031741846 scopus 로고    scopus 로고
    • Physical chemical properties of oral drug candidates in the discovery and exploratory development settings
    • Curatolo, W. (1998) Physical chemical properties of oral drug candidates in the discovery and exploratory development settings Pharm. Sci. Technol. Today 1, 387-393 10.1016/S1461-5347(98)00097-2
    • (1998) Pharm. Sci. Technol. Today , vol.1 , pp. 387-393
    • Curatolo, W.1
  • 78
    • 0034461768 scopus 로고    scopus 로고
    • Drug-like properties and the causes of poor solubility and poor permeability
    • Lipinski, C. A. (2000) Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 44, 235-249 10.1016/S1056-8719(00)00107-6
    • (2000) J. Pharmacol. Toxicol. Methods , vol.44 , pp. 235-249
    • Lipinski, C.A.1
  • 79
    • 0028948839 scopus 로고
    • A theoretical basis for a biopharmaceutics drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability
    • Amidon, G. L., Lennernas, H., Shah, V. P., and Crison, J. R. (1995) A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 12, 413-420 10.1023/A:1016212804288
    • (1995) Pharm. Res. , vol.12 , pp. 413-420
    • Amidon, G.L.1    Lennernas, H.2    Shah, V.P.3    Crison, J.R.4
  • 80
    • 33846176619 scopus 로고    scopus 로고
    • A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan
    • Takagi, T., Ramachandran, C., Bermejo, M., Yamashita, S., Yu, L. X., and Amidon, G. L. (2006) A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan Mol. Pharmaceutics 3, 631-643 10.1021/mp0600182
    • (2006) Mol. Pharmaceutics , vol.3 , pp. 631-643
    • Takagi, T.1    Ramachandran, C.2    Bermejo, M.3    Yamashita, S.4    Yu, L.X.5    Amidon, G.L.6
  • 81
    • 84889079603 scopus 로고    scopus 로고
    • Drug dissolution: Significance of physicochemical properties and physiological conditions
    • Jambhekar, S. S. and Breen, P. J. (2013) Drug dissolution: significance of physicochemical properties and physiological conditions Drug Discovery Today 18, 1173-1184 10.1016/j.drudis.2013.08.013
    • (2013) Drug Discovery Today , vol.18 , pp. 1173-1184
    • Jambhekar, S.S.1    Breen, P.J.2
  • 82
    • 84889087023 scopus 로고    scopus 로고
    • Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs
    • Vo, C. L., Park, C., and Lee, B. J. (2013) Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs Eur. J. Pharm. Biopharm. 85, 799-813 10.1016/j.ejpb.2013.09.007
    • (2013) Eur. J. Pharm. Biopharm. , vol.85 , pp. 799-813
    • Vo, C.L.1    Park, C.2    Lee, B.J.3
  • 83
    • 84941078541 scopus 로고    scopus 로고
    • Amorphous solid dispersions: Utilization and challenges in drug discovery and development
    • He, Y. and Ho, C. (2015) Amorphous solid dispersions: utilization and challenges in drug discovery and development J. Pharm. Sci. 104, 3237-3258 10.1002/jps.24541
    • (2015) J. Pharm. Sci. , vol.104 , pp. 3237-3258
    • He, Y.1    Ho, C.2
  • 84
    • 84863301279 scopus 로고    scopus 로고
    • A win-win solution in oral delivery of lipophilic drugs: Supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability
    • Miller, J. M., Beig, A., Carr, R. A., Spence, J. K., and Dahan, A. (2012) A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability Mol. Pharmaceutics 9, 2009-2016 10.1021/mp300104s
    • (2012) Mol. Pharmaceutics , vol.9 , pp. 2009-2016
    • Miller, J.M.1    Beig, A.2    Carr, R.A.3    Spence, J.K.4    Dahan, A.5
  • 85
    • 0019166075 scopus 로고
    • Solubility and partitioning 1: Solubility of nonelectrolytes in water
    • Yalkowsky, S. H. and Valvani, S. C. (1980) Solubility and partitioning 1: solubility of nonelectrolytes in water J. Pharm. Sci. 69, 912-922 10.1002/jps.2600690814
    • (1980) J. Pharm. Sci. , vol.69 , pp. 912-922
    • Yalkowsky, S.H.1    Valvani, S.C.2
  • 86
    • 0035138216 scopus 로고    scopus 로고
    • Estimation of the aqueous solubility 1: Application to organic nonelectrolytes
    • Jain, N. and Yalkowsky, S. H. (2001) Estimation of the aqueous solubility 1: application to organic nonelectrolytes J. Pharm. Sci. 90, 234-252 10.1002/1520-6017(200102)90:2<234::AID-JPS14>3.0.CO;2-V
    • (2001) J. Pharm. Sci. , vol.90 , pp. 234-252
    • Jain, N.1    Yalkowsky, S.H.2
  • 87
    • 0035263415 scopus 로고    scopus 로고
    • Prediction of drug solubility by the general solubility equation (GSE)
    • Ran, Y. and Yalkowsky, S. H. (2001) Prediction of drug solubility by the general solubility equation (GSE) J. Chem. Inf. Model. 41, 354-357 10.1021/ci000338c
    • (2001) J. Chem. Inf. Model. , vol.41 , pp. 354-357
    • Ran, Y.1    Yalkowsky, S.H.2
  • 88
    • 84863418861 scopus 로고    scopus 로고
    • Revisiting the general solubility equation: In silico prediction of aqueous solubility incorporating the effect of topographical polar surface area
    • Ali, J., Camilleri, P., Brown, M. B., Hutt, A. J., and Kirton, S. B. (2012) Revisiting the general solubility equation: in silico prediction of aqueous solubility incorporating the effect of topographical polar surface area J. Chem. Inf. Model. 52, 420-428 10.1021/ci200387c
    • (2012) J. Chem. Inf. Model. , vol.52 , pp. 420-428
    • Ali, J.1    Camilleri, P.2    Brown, M.B.3    Hutt, A.J.4    Kirton, S.B.5
  • 89
    • 36148933709 scopus 로고    scopus 로고
    • Poorly soluble marketed drugs display solvation limited solubility
    • Bergström, C. A., Wassvik, C. M., Johansson, K., and Hubatsch, I. (2007) Poorly soluble marketed drugs display solvation limited solubility J. Med. Chem. 50, 5858-5862 10.1021/jm0706416
    • (2007) J. Med. Chem. , vol.50 , pp. 5858-5862
    • Bergström, C.A.1    Wassvik, C.M.2    Johansson, K.3    Hubatsch, I.4
  • 91
    • 77957736510 scopus 로고    scopus 로고
    • Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant dissolution media
    • Fagerberg, J. H., Tsinman, O., Sun, N., Tsinman, K., Avdeef, A., and Bergström, C. A. (2010) Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant dissolution media Mol. Pharmaceutics 7, 1419-1430 10.1021/mp100049m
    • (2010) Mol. Pharmaceutics , vol.7 , pp. 1419-1430
    • Fagerberg, J.H.1    Tsinman, O.2    Sun, N.3    Tsinman, K.4    Avdeef, A.5    Bergström, C.A.6
  • 93
    • 77955509080 scopus 로고    scopus 로고
    • Getting physical in drug discovery: A contemporary perspective on solubility and hydrophobicity
    • Hill, A. P. and Young, R. J. (2010) Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity Drug Discovery Today 15, 648-655 10.1016/j.drudis.2010.05.016
    • (2010) Drug Discovery Today , vol.15 , pp. 648-655
    • Hill, A.P.1    Young, R.J.2
  • 94
    • 80052844344 scopus 로고    scopus 로고
    • Getting physical in drug discovery II: The impact of chromatographic hydrophobicity measurements and aromaticity
    • Young, R. J., Green, D. V., Luscombe, C. N., and Hill, A. P. (2011) Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity Drug Discovery Today 16, 822-830 10.1016/j.drudis.2011.06.001
    • (2011) Drug Discovery Today , vol.16 , pp. 822-830
    • Young, R.J.1    Green, D.V.2    Luscombe, C.N.3    Hill, A.P.4
  • 95
    • 84876698597 scopus 로고    scopus 로고
    • Increasing small molecule drug developability in sub-optimal chemical space
    • Ritchie, T. J., Macdonald, S. J. F., Peace, S., Pickett, S. D., and Luscombe, C. N. (2013) Increasing small molecule drug developability in sub-optimal chemical space MedChemComm 4, 673-680 10.1039/c3md00003f
    • (2013) MedChemComm , vol.4 , pp. 673-680
    • Ritchie, T.J.1    Macdonald, S.J.F.2    Peace, S.3    Pickett, S.D.4    Luscombe, C.N.5
  • 96
    • 69749091529 scopus 로고    scopus 로고
    • A consistent dataset of kinetic solubilities for early-phase drug discovery
    • Kramer, C., Heinisch, T., Fligge, T., Beck, B., and Clark, T. (2009) A consistent dataset of kinetic solubilities for early-phase drug discovery ChemMedChem 4, 1529-1536 10.1002/cmdc.200900205
    • (2009) ChemMedChem , vol.4 , pp. 1529-1536
    • Kramer, C.1    Heinisch, T.2    Fligge, T.3    Beck, B.4    Clark, T.5
  • 97
    • 39749181550 scopus 로고    scopus 로고
    • Generation of a set of simple, interpretable ADMET rules of thumb
    • Gleeson, M. P. (2008) Generation of a set of simple, interpretable ADMET rules of thumb J. Med. Chem. 51, 817-834 10.1021/jm701122q
    • (2008) J. Med. Chem. , vol.51 , pp. 817-834
    • Gleeson, M.P.1
  • 98
    • 0034729673 scopus 로고    scopus 로고
    • QSAR model for drug human oral bioavailability
    • Yoshida, F. and Topliss, J. G. (2000) QSAR model for drug human oral bioavailability J. Med. Chem. 43, 2575-2585 10.1021/jm0000564
    • (2000) J. Med. Chem. , vol.43 , pp. 2575-2585
    • Yoshida, F.1    Topliss, J.G.2
  • 99
    • 18744429213 scopus 로고    scopus 로고
    • Structural determinants of cytochrome P450 substrate specificity, binding affinity and catalytic rate
    • Lewis, D. F. V., Eddershaw, P. J., Dickins, M., Tarbit, M. H., and Goldfarb, P. S. (1998) Structural determinants of cytochrome P450 substrate specificity, binding affinity and catalytic rate Chem.-Biol. Interact. 115, 175-199 10.1016/S0009-2797(98)00068-4
    • (1998) Chem.-Biol. Interact. , vol.115 , pp. 175-199
    • Lewis, D.F.V.1    Eddershaw, P.J.2    Dickins, M.3    Tarbit, M.H.4    Goldfarb, P.S.5
  • 100
    • 0034600005 scopus 로고    scopus 로고
    • Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles
    • Lewis, D. F. V. (2000) Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles Toxicology 144, 197-203 10.1016/S0300-483X(99)00207-3
    • (2000) Toxicology , vol.144 , pp. 197-203
    • Lewis, D.F.V.1
  • 101
    • 0001280443 scopus 로고    scopus 로고
    • Substrate SARs in human P450s
    • Lewis, D. F. V. and Dickins, M. (2002) Substrate SARs in human P450s Drug Discovery Today 7, 918-925 10.1016/S1359-6446(02)02412-1
    • (2002) Drug Discovery Today , vol.7 , pp. 918-925
    • Lewis, D.F.V.1    Dickins, M.2
  • 102
    • 9644278194 scopus 로고    scopus 로고
    • Improving the decision-making process in the structural modification of drug candidates: Enhancing metabolic stability
    • Nassar, A. E., Kamel, A. M., and Clarimont, C. (2004) Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability Drug Discovery Today 9, 1020-1028 10.1016/S1359-6446(04)03280-5
    • (2004) Drug Discovery Today , vol.9 , pp. 1020-1028
    • Nassar, A.E.1    Kamel, A.M.2    Clarimont, C.3
  • 103
    • 69949109727 scopus 로고    scopus 로고
    • Using the golden triangle to optimize clearance and oral absorption
    • Johnson, T. W., Dress, K. R., and Edwards, M. (2009) Using the golden triangle to optimize clearance and oral absorption Bioorg. Med. Chem. Lett. 19, 5560-5564 10.1016/j.bmcl.2009.08.045
    • (2009) Bioorg. Med. Chem. Lett. , vol.19 , pp. 5560-5564
    • Johnson, T.W.1    Dress, K.R.2    Edwards, M.3
  • 104
    • 46449114275 scopus 로고    scopus 로고
    • Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds
    • Obach, R. S., Lombardo, F., and Waters, N. J. (2008) Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds Drug Metab. Dispos. 36, 1385-1405 10.1124/dmd.108.020479
    • (2008) Drug Metab. Dispos. , vol.36 , pp. 1385-1405
    • Obach, R.S.1    Lombardo, F.2    Waters, N.J.3
  • 105
    • 33746175746 scopus 로고    scopus 로고
    • Quantitative structure-activity relationships (QSARs) in CYP3A4 inhibitors: The importance of lipophilic character and hydrogen bonding
    • Lewis, D. F. V., Lake, B. G., and Dickins, M. (2006) Quantitative structure-activity relationships (QSARs) in CYP3A4 inhibitors: the importance of lipophilic character and hydrogen bonding J. Enzyme Inhib. Med. Chem. 21, 127-132 10.1080/14756360500532747
    • (2006) J. Enzyme Inhib. Med. Chem. , vol.21 , pp. 127-132
    • Lewis, D.F.V.1    Lake, B.G.2    Dickins, M.3
  • 106
    • 84916198560 scopus 로고    scopus 로고
    • Tactics to avoid inhibition of cytochrome P450s
    • Leach, A. G. (2013) Tactics to avoid inhibition of cytochrome P450s Top. Med. Chem. 9, 107-158 10.1007/7355-2013-25
    • (2013) Top. Med. Chem. , vol.9 , pp. 107-158
    • Leach, A.G.1
  • 107
    • 77957804992 scopus 로고    scopus 로고
    • Role of physicochemical properties and ligand lipophilicity efficiency in addressing drug safety risks
    • Edwards, M. P. and Price, D. A. (2010) Role of physicochemical properties and ligand lipophilicity efficiency in addressing drug safety risks Annu. Rep. Med. Chem. 45, 380-391 10.1016/S0065-7743(10)45023-X
    • (2010) Annu. Rep. Med. Chem. , vol.45 , pp. 380-391
    • Edwards, M.P.1    Price, D.A.2
  • 108
    • 77957806868 scopus 로고    scopus 로고
    • Reducing the risk of drug attrition associated with physicochemical properties
    • Leeson, P. D. and Empfield, J. R. (2010) Reducing the risk of drug attrition associated with physicochemical properties Annu. Rep. Med. Chem. 45, 393-407 10.1016/S0065-7743(10)45024-1
    • (2010) Annu. Rep. Med. Chem. , vol.45 , pp. 393-407
    • Leeson, P.D.1    Empfield, J.R.2
  • 110
    • 65549132575 scopus 로고    scopus 로고
    • Pharmacological promiscuity: Dependence on compound properties and target specificity in a set of recent Roche compounds
    • Peters, J.-E., Schnider, P., Mattei, P., and Kansy, M. (2009) Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds ChemMedChem 4, 680-686 10.1002/cmdc.200800411
    • (2009) ChemMedChem , vol.4 , pp. 680-686
    • Peters, J.-E.1    Schnider, P.2    Mattei, P.3    Kansy, M.4
  • 113
    • 33749042117 scopus 로고    scopus 로고
    • Drug-induced phospholipidosis
    • Anderson, N. and Borlak, J. (2006) Drug-induced phospholipidosis FEBS Lett. 580, 5533-5540 10.1016/j.febslet.2006.08.061
    • (2006) FEBS Lett. , vol.580 , pp. 5533-5540
    • Anderson, N.1    Borlak, J.2
  • 114
    • 68249083749 scopus 로고    scopus 로고
    • Screening for the drug-phospholipid interaction: Correlation to phospholipidosis
    • Alakoskela, J.-M., Vitovic, P., and Kinnunen, P. K. J. (2009) Screening for the drug-phospholipid interaction: correlation to phospholipidosis ChemMedChem 4, 1224-1251 10.1002/cmdc.200900052
    • (2009) ChemMedChem , vol.4 , pp. 1224-1251
    • Alakoskela, J.-M.1    Vitovic, P.2    Kinnunen, P.K.J.3
  • 115
    • 1842525842 scopus 로고    scopus 로고
    • Use of physicochemical calculation of p K a and CLog P to predict phospholipidosis-inducing potential: A case study with structurally related piperazines
    • Ploemen, J.-P. H. T. M., Kelder, J., Hafmans, T., van de Sandt, H., van Burgsteden, J. A., Saleminki, P. J., and van Esch, E. (2004) Use of physicochemical calculation of p K a and CLog P to predict phospholipidosis-inducing potential: a case study with structurally related piperazines Exp. Toxicol. Pathol. 55, 347-355 10.1078/0940-2993-00338
    • (2004) Exp. Toxicol. Pathol. , vol.55 , pp. 347-355
    • Ploemen, J.-P.H.T.M.1    Kelder, J.2    Hafmans, T.3    Van De Sandt, H.4    Van Burgsteden, J.A.5    Saleminki, P.J.6    Van Esch, E.7
  • 116
    • 34250791619 scopus 로고    scopus 로고
    • Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential
    • Pelletier, D. J., Gehlhaar, D., Tilloy-Ellul, A., Johnson, T. O., and Greene, N. (2007) Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential J. Chem. Inf. Model. 47, 1196-1205 10.1021/ci6004542
    • (2007) J. Chem. Inf. Model. , vol.47 , pp. 1196-1205
    • Pelletier, D.J.1    Gehlhaar, D.2    Tilloy-Ellul, A.3    Johnson, T.O.4    Greene, N.5
  • 117
    • 33750928793 scopus 로고    scopus 로고
    • Physicochemical and cell-based approach for early screening of phospholipidosis-inducing potential
    • Tomizawa, K., Sugano, K., Yamada, H., and Horii, I. (2006) Physicochemical and cell-based approach for early screening of phospholipidosis-inducing potential J. Toxicol. Sci. 31, 315-324 10.2131/jts.31.315
    • (2006) J. Toxicol. Sci. , vol.31 , pp. 315-324
    • Tomizawa, K.1    Sugano, K.2    Yamada, H.3    Horii, I.4
  • 118
    • 77951212394 scopus 로고    scopus 로고
    • Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds
    • Hanumegowda, U. M., Wenke, G., Regueiro-Ren, A., Yordanova, R., Corradi, J. P., and Adams, S. P. (2010) Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds Chem. Res. Toxicol. 23, 749-755 10.1021/tx9003825
    • (2010) Chem. Res. Toxicol. , vol.23 , pp. 749-755
    • Hanumegowda, U.M.1    Wenke, G.2    Regueiro-Ren, A.3    Yordanova, R.4    Corradi, J.P.5    Adams, S.P.6
  • 119
    • 70349489144 scopus 로고    scopus 로고
    • Medicinal chemistry strategies to minimize phospholipidosis
    • Ratcliffe, A. J. (2009) Medicinal chemistry strategies to minimize phospholipidosis Curr. Med. Chem. 16, 2816-2823 10.2174/092986709788803213
    • (2009) Curr. Med. Chem. , vol.16 , pp. 2816-2823
    • Ratcliffe, A.J.1
  • 121
    • 84864185732 scopus 로고    scopus 로고
    • Structure based model for the prediction of phospholipidosis induction potential of small molecules
    • Sun, H., Shahane, S., Xia, M., Austin, C. P., and Huang, R. (2012) Structure based model for the prediction of phospholipidosis induction potential of small molecules J. Chem. Inf. Model. 52, 1798-1805 10.1021/ci3001875
    • (2012) J. Chem. Inf. Model. , vol.52 , pp. 1798-1805
    • Sun, H.1    Shahane, S.2    Xia, M.3    Austin, C.P.4    Huang, R.5
  • 122
    • 84855856561 scopus 로고    scopus 로고
    • In silico assay for assessing phospholipidosis potential of small drug like molecules: Training, validation, and refinement using several data sets
    • Fischer, H., Atzpodien, E. A., Csato, M., Doessegger, L., Lenz, B., Schmitt, G., and Singer, T. (2012) In silico assay for assessing phospholipidosis potential of small drug like molecules: training, validation, and refinement using several data sets J. Med. Chem. 55, 126-139 10.1021/jm201082a
    • (2012) J. Med. Chem. , vol.55 , pp. 126-139
    • Fischer, H.1    Atzpodien, E.A.2    Csato, M.3    Doessegger, L.4    Lenz, B.5    Schmitt, G.6    Singer, T.7
  • 123
    • 33847336843 scopus 로고    scopus 로고
    • A quantitative assessment of hERG liability as a function of lipophilicity
    • Waring, M. J. and Johnstone, C. (2007) A quantitative assessment of hERG liability as a function of lipophilicity Bioorg. Med. Chem. Lett. 17, 1759-1764 10.1016/j.bmcl.2006.12.061
    • (2007) Bioorg. Med. Chem. Lett. , vol.17 , pp. 1759-1764
    • Waring, M.J.1    Johnstone, C.2
  • 124
    • 80052282205 scopus 로고    scopus 로고
    • A risk assessment of human ether-à-go-go-related gene potassium channel inhibition by using lipophilicity and basicity for drug discovery
    • Kawai, Y., Tsukamoto, S., Ito, J., Akimoto, K., and Takahashi, M. (2011) A risk assessment of human ether-à-go-go-related gene potassium channel inhibition by using lipophilicity and basicity for drug discovery Chem. Pharm. Bull. 59, 1110-1116 10.1248/cpb.59.1110
    • (2011) Chem. Pharm. Bull. , vol.59 , pp. 1110-1116
    • Kawai, Y.1    Tsukamoto, S.2    Ito, J.3    Akimoto, K.4    Takahashi, M.5
  • 125
    • 84937629636 scopus 로고    scopus 로고
    • Computational investigations of hERG channel blockers: New insights and current predictive models
    • Villoutreix, B. O. and Taboureau, O. (2015) Computational investigations of hERG channel blockers: new insights and current predictive models Adv. Drug Delivery Rev. 86, 72-82 10.1016/j.addr.2015.03.003
    • (2015) Adv. Drug Delivery Rev. , vol.86 , pp. 72-82
    • Villoutreix, B.O.1    Taboureau, O.2
  • 126
    • 84860359784 scopus 로고    scopus 로고
    • Finding the sweet spot: The role of nature and nurture in medicinal chemistry
    • Hann, M. M. and Keserü, G. M. (2012) Finding the sweet spot: the role of nature and nurture in medicinal chemistry Nat. Rev. Drug Discovery 11, 355-365 10.1038/nrd3701
    • (2012) Nat. Rev. Drug Discovery , vol.11 , pp. 355-365
    • Hann, M.M.1    Keserü, G.M.2
  • 128
    • 84885190072 scopus 로고    scopus 로고
    • The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations
    • Shultz, M. D. (2013) The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations Bioorg. Med. Chem. Lett. 23, 5992-6000 10.1016/j.bmcl.2013.08.030
    • (2013) Bioorg. Med. Chem. Lett. , vol.23 , pp. 5992-6000
    • Shultz, M.D.1
  • 129
    • 37049036372 scopus 로고    scopus 로고
    • Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier
    • Dierynck, I., De Wit, M., Gustin, E., Keuleers, I., Vandersmissen, J., Hallenberger, S., and Hertogs, K. (2007) Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier J. Virol. 81, 13845-13851 10.1128/JVI.01184-07
    • (2007) J. Virol. , vol.81 , pp. 13845-13851
    • Dierynck, I.1    De Wit, M.2    Gustin, E.3    Keuleers, I.4    Vandersmissen, J.5    Hallenberger, S.6    Hertogs, K.7
  • 130
    • 80051799265 scopus 로고    scopus 로고
    • Assessing the lipophilicity of fragments and early hits
    • Mortenson, P. N. and Murray, C. W. (2011) Assessing the lipophilicity of fragments and early hits J. Comput.-Aided Mol. Des. 25, 663-667 10.1007/s10822-011-9435-z
    • (2011) J. Comput.-Aided Mol. Des. , vol.25 , pp. 663-667
    • Mortenson, P.N.1    Murray, C.W.2
  • 131
    • 61649109015 scopus 로고    scopus 로고
    • The influence of lead discovery strategies on the properties of drug candidates
    • Keserü, G. M. and Makara, G. M. (2009) The influence of lead discovery strategies on the properties of drug candidates Nat. Rev. Drug Discovery 8, 203-212 10.1038/nrd2796
    • (2009) Nat. Rev. Drug Discovery , vol.8 , pp. 203-212
    • Keserü, G.M.1    Makara, G.M.2
  • 132
    • 84856846240 scopus 로고    scopus 로고
    • Impact of lipophilic efficiency on compound quality
    • Tarcsay, A., Nyíri, K., and Keseru{combining double acute accent}, G. M. (2012) Impact of lipophilic efficiency on compound quality J. Med. Chem. 55, 1252-1260 10.1021/jm201388p
    • (2012) J. Med. Chem. , vol.55 , pp. 1252-1260
    • Tarcsay, A.1    Nyíri, K.2    Keseru, G.M.3
  • 134
    • 80054782568 scopus 로고    scopus 로고
    • The successful quest for oral factor Xa inhibitors, learnings for all of medicinal chemistry?
    • Young, R. J. (2011) The successful quest for oral factor Xa inhibitors, learnings for all of medicinal chemistry? Bioorg. Med. Chem. Lett. 21, 6228-6235 10.1016/j.bmcl.2011.08.119
    • (2011) Bioorg. Med. Chem. Lett. , vol.21 , pp. 6228-6235
    • Young, R.J.1
  • 135
    • 33845937770 scopus 로고    scopus 로고
    • Structure-brain exposure relationships
    • Hitchcock, S. A. and Pennington, L. D. (2006) Structure-brain exposure relationships J. Med. Chem. 49, 7559-7583 10.1021/jm060642i
    • (2006) J. Med. Chem. , vol.49 , pp. 7559-7583
    • Hitchcock, S.A.1    Pennington, L.D.2
  • 136
    • 84856046963 scopus 로고    scopus 로고
    • Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery
    • Ghose, A. K., Herbertz, T., Hudkins, R. L., Dorsey, B. D., and Mallamo, J. P. (2012) Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery ACS Chem. Neurosci. 3, 50-68 10.1021/cn200100h
    • (2012) ACS Chem. Neurosci. , vol.3 , pp. 50-68
    • Ghose, A.K.1    Herbertz, T.2    Hudkins, R.L.3    Dorsey, B.D.4    Mallamo, J.P.5
  • 138
    • 84925854124 scopus 로고    scopus 로고
    • CNS drug design: Balancing physicochemical properties for optimal brain exposure
    • Rankovic, Z. (2015) CNS drug design: balancing physicochemical properties for optimal brain exposure J. Med. Chem. 58, 2584-2608 10.1021/jm501535r
    • (2015) J. Med. Chem. , vol.58 , pp. 2584-2608
    • Rankovic, Z.1
  • 139
    • 77953680038 scopus 로고    scopus 로고
    • Defining desirable central nervous system drug space through alignment of molecular properties, in vitro ADME, and safety attributes
    • Wager, T. T., Chandrasekaran, R. Y., Hou, X., Troutman, M. D., Verhoest, P. R., Villalobos, A., and Will, Y. (2010) Defining desirable central nervous system drug space through alignment of molecular properties, in vitro ADME, and safety attributes ACS Chem. Neurosci. 1, 420-434 10.1021/cn100007x
    • (2010) ACS Chem. Neurosci. , vol.1 , pp. 420-434
    • Wager, T.T.1    Chandrasekaran, R.Y.2    Hou, X.3    Troutman, M.D.4    Verhoest, P.R.5    Villalobos, A.6    Will, Y.7
  • 140
    • 77953675980 scopus 로고    scopus 로고
    • Moving beyond rules: The development of a central nervous system mulitparameter optimization (CNS MPO) approach to enable alignment of druglike properties
    • Wager, T. T., Hou, X., Verhoest, P. R., and Villalobos, A. (2010) Moving beyond rules: the development of a central nervous system mulitparameter optimization (CNS MPO) approach to enable alignment of druglike properties ACS Chem. Neurosci. 1, 435-449 10.1021/cn100008c
    • (2010) ACS Chem. Neurosci. , vol.1 , pp. 435-449
    • Wager, T.T.1    Hou, X.2    Verhoest, P.R.3    Villalobos, A.4
  • 141
    • 84867577372 scopus 로고    scopus 로고
    • How hydrogen bonds impact P-glycoprotein transport and permeability
    • Desai, P. V., Raub, T. J., and Blanco, M. J. (2012) How hydrogen bonds impact P-glycoprotein transport and permeability Bioorg. Med. Chem. Lett. 22, 6540-6548 10.1016/j.bmcl.2012.08.059
    • (2012) Bioorg. Med. Chem. Lett. , vol.22 , pp. 6540-6548
    • Desai, P.V.1    Raub, T.J.2    Blanco, M.J.3
  • 142
    • 84862296187 scopus 로고    scopus 로고
    • Structural modifications that alter the P-glycoprotein efflux properties of compounds
    • Hitchcock, S. A. (2012) Structural modifications that alter the P-glycoprotein efflux properties of compounds J. Med. Chem. 55, 4877-4895 10.1021/jm201136z
    • (2012) J. Med. Chem. , vol.55 , pp. 4877-4895
    • Hitchcock, S.A.1
  • 143
    • 1442301563 scopus 로고    scopus 로고
    • How significant is the role of P-glycoprotein in drug absorption and brain uptake?
    • Lin, J. H. (2004) How significant is the role of P-glycoprotein in drug absorption and brain uptake? Drugs Today 40, 5-22 10.1358/dot.2004.40.1.799434
    • (2004) Drugs Today , vol.40 , pp. 5-22
    • Lin, J.H.1
  • 144
    • 33144479357 scopus 로고    scopus 로고
    • Role of ABCG2/BCRP in biology and medicine
    • Krishnamurthy, P. and Schuetz, J. D. (2006) Role of ABCG2/BCRP in biology and medicine Annu. Rev. Pharmacol. Toxicol. 46, 381-410 10.1146/annurev.pharmtox.46.120604.141238
    • (2006) Annu. Rev. Pharmacol. Toxicol. , vol.46 , pp. 381-410
    • Krishnamurthy, P.1    Schuetz, J.D.2
  • 145
    • 30344487254 scopus 로고    scopus 로고
    • Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs
    • Breedveld, P., Beijnen, J. H., and Schellens, J. H. (2006) Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs Trends Pharmacol. Sci. 27, 17-24 10.1016/j.tips.2005.11.009
    • (2006) Trends Pharmacol. Sci. , vol.27 , pp. 17-24
    • Breedveld, P.1    Beijnen, J.H.2    Schellens, J.H.3
  • 146
    • 84941584887 scopus 로고    scopus 로고
    • Chemical biology of leucine-rich repeat kinase 2 (LRRK2) inhibitors
    • Estrada, A. A. and Sweeney, Z. K. (2015) Chemical biology of leucine-rich repeat kinase 2 (LRRK2) inhibitors J. Med. Chem. 58, 6733-6746 10.1021/acs.jmedchem.5b00261
    • (2015) J. Med. Chem. , vol.58 , pp. 6733-6746
    • Estrada, A.A.1    Sweeney, Z.K.2
  • 147
    • 84955468444 scopus 로고    scopus 로고
    • Probabilistic approach to generating MPOs and its application as a scoring function for CNS drugs
    • Gunaydin, H. (2016) Probabilistic approach to generating MPOs and its application as a scoring function for CNS drugs ACS Med. Chem. Lett. 7, 89-93 10.1021/acsmedchemlett.5b00390
    • (2016) ACS Med. Chem. Lett. , vol.7 , pp. 89-93
    • Gunaydin, H.1
  • 148
    • 0031024171 scopus 로고    scopus 로고
    • Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
    • Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P. J. (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 23, 3-25 10.1016/S0169-409X(96)00423-1
    • (1997) Adv. Drug Delivery Rev. , vol.23 , pp. 3-25
    • Lipinski, C.A.1    Lombardo, F.2    Dominy, B.W.3    Feeney, P.J.4
  • 149
    • 84866244593 scopus 로고    scopus 로고
    • Softening the rule of five - Where to draw the line?
    • Petit, J., Meurice, N., Kaiser, C., and Maggiora, G. (2012) Softening the rule of five-where to draw the line? Bioorg. Med. Chem. 20, 5343-5351 10.1016/j.bmc.2011.11.064
    • (2012) Bioorg. Med. Chem. , vol.20 , pp. 5343-5351
    • Petit, J.1    Meurice, N.2    Kaiser, C.3    Maggiora, G.4
  • 151
    • 37549071045 scopus 로고    scopus 로고
    • Drug discovery beyond the 'rule-of-five'
    • Zhang, M. Q. and Wilkinson, B. (2007) Drug discovery beyond the 'rule-of-five' Curr. Opin. Biotechnol. 18, 478-488 10.1016/j.copbio.2007.10.005
    • (2007) Curr. Opin. Biotechnol. , vol.18 , pp. 478-488
    • Zhang, M.Q.1    Wilkinson, B.2
  • 152
    • 0037030653 scopus 로고    scopus 로고
    • Molecular properties that influence the oral bioavailability of drug candidates
    • Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., and Kopple, K. D. (2002) Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 45, 2615-2623 10.1021/jm020017n
    • (2002) J. Med. Chem. , vol.45 , pp. 2615-2623
    • Veber, D.F.1    Johnson, S.R.2    Cheng, H.-Y.3    Smith, B.R.4    Ward, K.W.5    Kopple, K.D.6
  • 155
    • 79958266864 scopus 로고    scopus 로고
    • ADME evaluation in drug discovery. 9. Prediction of oral bioavailability in humans based on molecular properties and structural fingerprints
    • Tian, S., Li, Y., Wang, J., Zhang, J., and Hou, T. (2011) ADME evaluation in drug discovery. 9. Prediction of oral bioavailability in humans based on molecular properties and structural fingerprints Mol. Pharmaceutics 8, 841-851 10.1021/mp100444g
    • (2011) Mol. Pharmaceutics , vol.8 , pp. 841-851
    • Tian, S.1    Li, Y.2    Wang, J.3    Zhang, J.4    Hou, T.5
  • 156
    • 78650699097 scopus 로고    scopus 로고
    • Molecular topology analysis of the differences between drugs, clinical candidate compounds, and bioactive molecules
    • Chen, H., Yang, Y., and Engkvist, O. (2010) Molecular topology analysis of the differences between drugs, clinical candidate compounds, and bioactive molecules J. Chem. Inf. Model. 50, 2141-2150 10.1021/ci1002558
    • (2010) J. Chem. Inf. Model. , vol.50 , pp. 2141-2150
    • Chen, H.1    Yang, Y.2    Engkvist, O.3
  • 157
    • 78149236457 scopus 로고    scopus 로고
    • Investigation of the relationship between topology and selectivity for druglike molecules
    • Yang, Y., Chen, H., Nilsson, I., Muresan, S., and Engkvist, O. (2010) Investigation of the relationship between topology and selectivity for druglike molecules J. Med. Chem. 53, 7709-7714 10.1021/jm1008456
    • (2010) J. Med. Chem. , vol.53 , pp. 7709-7714
    • Yang, Y.1    Chen, H.2    Nilsson, I.3    Muresan, S.4    Engkvist, O.5
  • 158
    • 84863251729 scopus 로고    scopus 로고
    • A comparative analysis of the molecular topologies for drugs, clinical candidates, natural products, human metabolites and general bioactive compounds
    • Chen, H., Engkvist, O., Blomberg, N., and Li, J. (2012) A comparative analysis of the molecular topologies for drugs, clinical candidates, natural products, human metabolites and general bioactive compounds MedChemComm 3, 312-321 10.1039/C2MD00238H
    • (2012) MedChemComm , vol.3 , pp. 312-321
    • Chen, H.1    Engkvist, O.2    Blomberg, N.3    Li, J.4
  • 159
    • 84860267055 scopus 로고    scopus 로고
    • Beyond size, ionization state, and lipophilicity: Influence of molecular topology on absorption, distribution, metabolism, excretion, and toxicity for druglike compounds
    • Yang, Y., Engkvist, O., Llinàs, A., and Chen, H. (2012) Beyond size, ionization state, and lipophilicity: influence of molecular topology on absorption, distribution, metabolism, excretion, and toxicity for druglike compounds J. Med. Chem. 55, 3667-3677 10.1021/jm201548z
    • (2012) J. Med. Chem. , vol.55 , pp. 3667-3677
    • Yang, Y.1    Engkvist, O.2    Llinàs, A.3    Chen, H.4
  • 161
    • 71049126548 scopus 로고    scopus 로고
    • Escape from flatland: Increasing saturation as an approach to improving clinical success
    • Lovering, F., Bikker, J., and Humblet, C. (2009) Escape from flatland: increasing saturation as an approach to improving clinical success J. Med. Chem. 52, 6752-6756 10.1021/jm901241e
    • (2009) J. Med. Chem. , vol.52 , pp. 6752-6756
    • Lovering, F.1    Bikker, J.2    Humblet, C.3
  • 162
    • 84874464077 scopus 로고    scopus 로고
    • Escape from flatland 2: Complexity and promiscuity
    • Lovering, F. (2013) Escape from flatland 2: complexity and promiscuity MedChemComm 4, 515-519 10.1039/c2md20347b
    • (2013) MedChemComm , vol.4 , pp. 515-519
    • Lovering, F.1
  • 163
    • 78650459806 scopus 로고    scopus 로고
    • Small molecules of different synthetic and natural origins have distinct distributions of structural complexity that correlate with protein binding profiles
    • Clemons, P. A., Bodycombe, N. E., Carrinski, H. A., Wilson, J. A., Shamji, A. F., Wagner, B. K., Koehler, A. N., and Schreiber, S. L. (2010) Small molecules of different synthetic and natural origins have distinct distributions of structural complexity that correlate with protein binding profiles Proc. Natl. Acad. Sci. U. S. A. 107, 18787-18792 10.1073/pnas.1012741107
    • (2010) Proc. Natl. Acad. Sci. U. S. A. , vol.107 , pp. 18787-18792
    • Clemons, P.A.1    Bodycombe, N.E.2    Carrinski, H.A.3    Wilson, J.A.4    Shamji, A.F.5    Wagner, B.K.6    Koehler, A.N.7    Schreiber, S.L.8
  • 164
    • 77955816970 scopus 로고    scopus 로고
    • Distinct biological network properties between the targets of natural products and disease genes
    • Dancik, V., Seiler, K. P., Young, D. W., Schreiber, S. L., and Clemons, P. A. (2010) Distinct biological network properties between the targets of natural products and disease genes J. Am. Chem. Soc. 132, 9259-9261 10.1021/ja102798t
    • (2010) J. Am. Chem. Soc. , vol.132 , pp. 9259-9261
    • Dancik, V.1    Seiler, K.P.2    Young, D.W.3    Schreiber, S.L.4    Clemons, P.A.5
  • 165
    • 0037208308 scopus 로고    scopus 로고
    • Property distributions: Differences between drugs, natural products, and molecules from combinatorial chemistry
    • Feher, M. and Schmidt, J. M. (2003) Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry J. Chem. Inf. Model. 43, 218-227 10.1021/ci0200467
    • (2003) J. Chem. Inf. Model. , vol.43 , pp. 218-227
    • Feher, M.1    Schmidt, J.M.2
  • 166
    • 78649335410 scopus 로고    scopus 로고
    • Characteristics of known drug space. Natural products, their derivatives and synthetic drugs
    • Bade, R., Chan, H. F., and Reynisson, J. (2010) Characteristics of known drug space. Natural products, their derivatives and synthetic drugs Eur. J. Med. Chem. 45, 5646-5652 10.1016/j.ejmech.2010.09.018
    • (2010) Eur. J. Med. Chem. , vol.45 , pp. 5646-5652
    • Bade, R.1    Chan, H.F.2    Reynisson, J.3
  • 167
    • 84933056390 scopus 로고    scopus 로고
    • Analysis of physicochemical properties for drugs of natural origin
    • Camp, D., Garavelas, A., and Campitelli, M. (2015) Analysis of physicochemical properties for drugs of natural origin J. Nat. Prod. 78, 1370-1382 10.1021/acs.jnatprod.5b00255
    • (2015) J. Nat. Prod. , vol.78 , pp. 1370-1382
    • Camp, D.1    Garavelas, A.2    Campitelli, M.3
  • 168
    • 84944274915 scopus 로고    scopus 로고
    • Cheminformatic comparison of approved drugs from natural product versus synthetic origins
    • Stratton, C. F., Newman, D. J., and Tan, D. S. (2015) Cheminformatic comparison of approved drugs from natural product versus synthetic origins Bioorg. Med. Chem. Lett. 25, 4802-4807 10.1016/j.bmcl.2015.07.014
    • (2015) Bioorg. Med. Chem. Lett. , vol.25 , pp. 4802-4807
    • Stratton, C.F.1    Newman, D.J.2    Tan, D.S.3
  • 169
    • 70350409235 scopus 로고    scopus 로고
    • The impact of aromatic ring count on compound developability - Are too many aromatic rings a liability in drug design?
    • Ritchie, T. R. and Macdonald, S. J. F. (2009) The impact of aromatic ring count on compound developability-are too many aromatic rings a liability in drug design? Drug Discovery Today 14, 1011-1020 10.1016/j.drudis.2009.07.014
    • (2009) Drug Discovery Today , vol.14 , pp. 1011-1020
    • Ritchie, T.R.1    Macdonald, S.J.F.2
  • 170
    • 79851514554 scopus 로고    scopus 로고
    • The impact of aromatic ring count on compound developability: Further insights by examining carbo- and hetero-aromatic and -aliphatic ring types
    • Ritchie, T. R., Macdonald, S. J. F., Young, R. J., and Pickett, S. D. (2011) The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types Drug Discovery Today 16, 164-171 10.1016/j.drudis.2010.11.014
    • (2011) Drug Discovery Today , vol.16 , pp. 164-171
    • Ritchie, T.R.1    Macdonald, S.J.F.2    Young, R.J.3    Pickett, S.D.4
  • 171
    • 44049092515 scopus 로고    scopus 로고
    • Straightforward recursive partition model for discarding insoluble compounds in the drug discovery process
    • Lamanna, C., Bellini, M., Padova, A., Westerberg, G., and Maccari, L. (2008) Straightforward recursive partition model for discarding insoluble compounds in the drug discovery process J. Med. Chem. 51, 2891-2897 10.1021/jm701407x
    • (2008) J. Med. Chem. , vol.51 , pp. 2891-2897
    • Lamanna, C.1    Bellini, M.2    Padova, A.3    Westerberg, G.4    Maccari, L.5
  • 172
    • 84890097215 scopus 로고    scopus 로고
    • Impact of physicochemical profiling for rational approach to drug discovery
    • Nakashima, S., Yamamoto, K., Arai, Y., and Ikeda, Y. (2013) Impact of physicochemical profiling for rational approach to drug discovery Chem. Pharm. Bull. 61, 1228-1238 10.1248/cpb.c13-00436
    • (2013) Chem. Pharm. Bull. , vol.61 , pp. 1228-1238
    • Nakashima, S.1    Yamamoto, K.2    Arai, Y.3    Ikeda, Y.4
  • 173
    • 79952804851 scopus 로고    scopus 로고
    • Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry
    • Ishikawa, M. and Hashimoto, Y. (2011) Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry J. Med. Chem. 54, 1539-1554 10.1021/jm101356p
    • (2011) J. Med. Chem. , vol.54 , pp. 1539-1554
    • Ishikawa, M.1    Hashimoto, Y.2
  • 174
    • 84912015874 scopus 로고    scopus 로고
    • Novel tactics for designing water-soluble molecules in drug discovery
    • Walker, M. A. (2014) Novel tactics for designing water-soluble molecules in drug discovery Expert Opin. Drug Discovery 9, 1421-1433 10.1517/17460441.2014.960839
    • (2014) Expert Opin. Drug Discovery , vol.9 , pp. 1421-1433
    • Walker, M.A.1
  • 175
    • 84907168648 scopus 로고    scopus 로고
    • Physicochemical descriptors of aromatic character and their use in drug discovery
    • Ritchie, T. J. and Macdonald, S. J. (2014) Physicochemical descriptors of aromatic character and their use in drug discovery J. Med. Chem. 57, 7206-7215 10.1021/jm500515d
    • (2014) J. Med. Chem. , vol.57 , pp. 7206-7215
    • Ritchie, T.J.1    Macdonald, S.J.2
  • 176
    • 79957698619 scopus 로고    scopus 로고
    • The medicinal chemist's toolbox: An analysis of reactions used in the pursuit of drug candidates
    • Roughley, S. D. and Jordan, A. M. (2011) The medicinal chemist's toolbox: an analysis of reactions used in the pursuit of drug candidates J. Med. Chem. 54, 3451-3479 10.1021/jm200187y
    • (2011) J. Med. Chem. , vol.54 , pp. 3451-3479
    • Roughley, S.D.1    Jordan, A.M.2
  • 178
    • 84969617464 scopus 로고    scopus 로고
    • An analysis of past and present synthetic methodologies on medicinal chemistry: Where have all the new reactions gone?
    • Brown, D. G. and Boström, J. (2015) An analysis of past and present synthetic methodologies on medicinal chemistry: where have all the new reactions gone? J. Med. Chem. 10.1021/acs.jmedchem.5b01409
    • (2015) J. Med. Chem.
    • Brown, D.G.1    Boström, J.2
  • 179
    • 84922629203 scopus 로고    scopus 로고
    • Transition metal catalyzed meta-C-H functionalization of aromatic compounds
    • Yang, J. (2015) Transition metal catalyzed meta-C-H functionalization of aromatic compounds Org. Biomol. Chem. 13, 1930-1941 10.1039/C4OB02171A
    • (2015) Org. Biomol. Chem. , vol.13 , pp. 1930-1941
    • Yang, J.1
  • 180
    • 84863446276 scopus 로고    scopus 로고
    • Weak coordination as a powerful means for developing broadly useful C-H functionalization reactions
    • Engle, K. M., Mei, T. S., Wasa, M., and Yu, J.-Q. (2012) Weak coordination as a powerful means for developing broadly useful C-H functionalization reactions Acc. Chem. Res. 45, 788-802 10.1021/ar200185g
    • (2012) Acc. Chem. Res. , vol.45 , pp. 788-802
    • Engle, K.M.1    Mei, T.S.2    Wasa, M.3    Yu, J.-Q.4
  • 181
    • 84863451341 scopus 로고    scopus 로고
    • Controlling site selectivity in palladium-catalyzed C-H bond functionalization
    • Neufeldt, S. R. and Sanford, M. S. (2012) Controlling site selectivity in palladium-catalyzed C-H bond functionalization Acc. Chem. Res. 45, 936-946 10.1021/ar300014f
    • (2012) Acc. Chem. Res. , vol.45 , pp. 936-946
    • Neufeldt, S.R.1    Sanford, M.S.2
  • 182
    • 84948705270 scopus 로고    scopus 로고
    • Oxidative coupling between two hydrocarbons: An update of recent C-H functionalizations
    • Liu, C., Yuan, J., Gao, M., Tang, S., Li, W., Shi, R., and Lei, A. (2015) Oxidative coupling between two hydrocarbons: an update of recent C-H functionalizations Chem. Rev. 115, 12138-12204 10.1021/cr500431s
    • (2015) Chem. Rev. , vol.115 , pp. 12138-12204
    • Liu, C.1    Yuan, J.2    Gao, M.3    Tang, S.4    Li, W.5    Shi, R.6    Lei, A.7
  • 185
    • 84889850852 scopus 로고    scopus 로고
    • Recent trends in Pd-catalyzed remote functionalization of carbonyl compounds
    • Franzoni, I. and Mazet, C. (2014) Recent trends in Pd-catalyzed remote functionalization of carbonyl compounds Org. Biomol. Chem. 12, 233-241 10.1039/C3OB42050G
    • (2014) Org. Biomol. Chem. , vol.12 , pp. 233-241
    • Franzoni, I.1    Mazet, C.2
  • 186
    • 84959036973 scopus 로고    scopus 로고
    • 3)-H olefination of amines: En route to pyrrolidines
    • 3)-H olefination of amines: en route to pyrrolidines J. Am. Chem. Soc. 138, 2055 10.1021/jacs.5b13462
    • (2016) J. Am. Chem. Soc. , vol.138 , pp. 2055
    • Jiang, H.1    He, J.2    Liu, T.3    Yu, J.-Q.4
  • 187
    • 80054972215 scopus 로고    scopus 로고
    • 3)-H bonds
    • 3)-H bonds Chem. Soc. Rev. 40, 4902-4911 10.1039/c1cs15058h
    • (2011) Chem. Soc. Rev. , vol.40 , pp. 4902-4911
    • Baudoin, O.1
  • 188
    • 0029848429 scopus 로고    scopus 로고
    • Principal components describing biological activities and molecular diversity of heterocyclic aromatic ring fragments
    • Gibson, S., McGuire, R., and Rees, D. C. (1996) Principal components describing biological activities and molecular diversity of heterocyclic aromatic ring fragments J. Med. Chem. 39, 4065-4072 10.1021/jm960058h
    • (1996) J. Med. Chem. , vol.39 , pp. 4065-4072
    • Gibson, S.1    McGuire, R.2    Rees, D.C.3
  • 189
    • 84864997030 scopus 로고    scopus 로고
    • Pharmacological significance of synthetic heterocycles scaffold: A review
    • Dua, R., Shrivastava, S., Sonwane, S. K., and Srivastava, S. K. (2011) Pharmacological significance of synthetic heterocycles scaffold: a review Adv. Biol. Res. 5, 120-144
    • (2011) Adv. Biol. Res. , vol.5 , pp. 120-144
    • Dua, R.1    Shrivastava, S.2    Sonwane, S.K.3    Srivastava, S.K.4
  • 191
    • 4344612574 scopus 로고    scopus 로고
    • Selection of heterocycles for drug design
    • Broughton, H. B. and Watson, I. A. (2004) Selection of heterocycles for drug design J. Mol. Graphics Modell. 23, 51-58 10.1016/j.jmgm.2004.03.016
    • (2004) J. Mol. Graphics Modell. , vol.23 , pp. 51-58
    • Broughton, H.B.1    Watson, I.A.2
  • 192
    • 84929384579 scopus 로고    scopus 로고
    • A survey of the role of noncovalent sulfur interactions in drug design
    • Beno, B. R., Yeung, K. S., Bartberger, M. D., Pennington, L. D., and Meanwell, N. A. (2015) A survey of the role of noncovalent sulfur interactions in drug design J. Med. Chem. 58, 4383-4438 10.1021/jm501853m
    • (2015) J. Med. Chem. , vol.58 , pp. 4383-4438
    • Beno, B.R.1    Yeung, K.S.2    Bartberger, M.D.3    Pennington, L.D.4    Meanwell, N.A.5
  • 193
    • 0025995750 scopus 로고
    • Isosterism and bioisosterism in drug design
    • Burger, A. (1991) Isosterism and bioisosterism in drug design Prog. Drug Res. 37, 287-371 10.1007/978-3-0348-7139-6-7
    • (1991) Prog. Drug Res. , vol.37 , pp. 287-371
    • Burger, A.1
  • 194
    • 7744243992 scopus 로고    scopus 로고
    • Bioisosterism: A rational approach in drug design
    • Patani, G. A. and LaVoie, E. J. (1996) Bioisosterism: a rational approach in drug design Chem. Rev. 96, 3147-3176 10.1021/cr950066q
    • (1996) Chem. Rev. , vol.96 , pp. 3147-3176
    • Patani, G.A.1    LaVoie, E.J.2
  • 195
    • 79955419410 scopus 로고    scopus 로고
    • Synopsis of some recent tactical application of bioisosteres in drug design
    • Meanwell, N. A. (2011) Synopsis of some recent tactical application of bioisosteres in drug design J. Med. Chem. 54, 2529-2591 10.1021/jm1013693
    • (2011) J. Med. Chem. , vol.54 , pp. 2529-2591
    • Meanwell, N.A.1
  • 196
    • 84865491027 scopus 로고    scopus 로고
    • The developability of heteroaromatic and heteroaliphatic rings - Do some have a better pedigree as potential drug molecules than others?
    • Ritchie, T. J., Macdonald, S. J. F., Peace, S., Pickett, S. D., and Luscombe, C. N. (2012) The developability of heteroaromatic and heteroaliphatic rings-do some have a better pedigree as potential drug molecules than others? MedChemComm 3, 1062-1069 10.1039/c2md20111a
    • (2012) MedChemComm , vol.3 , pp. 1062-1069
    • Ritchie, T.J.1    Macdonald, S.J.F.2    Peace, S.3    Pickett, S.D.4    Luscombe, C.N.5
  • 200
    • 84874311050 scopus 로고    scopus 로고
    • Efficient stacking on protein amide fragments
    • Harder, M., Kuhn, B., and Diederich, F. (2013) Efficient stacking on protein amide fragments ChemMedChem 8, 397-404 10.1002/cmdc.201200512
    • (2013) ChemMedChem , vol.8 , pp. 397-404
    • Harder, M.1    Kuhn, B.2    Diederich, F.3
  • 201
    • 67650763061 scopus 로고    scopus 로고
    • The pKBHX database: Toward a better understanding of hydrogen-bond basicity for medicinal chemists
    • Laurence, C., Brameld, K. A., Graton, J., Le Questel, J.-Y., and Renault, E. (2009) The pKBHX database: toward a better understanding of hydrogen-bond basicity for medicinal chemists J. Med. Chem. 52, 4073-4086 10.1021/jm801331y
    • (2009) J. Med. Chem. , vol.52 , pp. 4073-4086
    • Laurence, C.1    Brameld, K.A.2    Graton, J.3    Le Questel, J.-Y.4    Renault, E.5
  • 202
    • 37049068888 scopus 로고
    • Hydrogen bonding. Part 9. Solute proton donor and proton acceptor scales for use in drug design
    • Abraham, M. H., Duce, P. P., and Prior, D. V. (1989) Hydrogen bonding. Part 9. Solute proton donor and proton acceptor scales for use in drug design J. Chem. Soc., Perkin Trans. 2 2, 1355-1375 10.1039/p29890001355
    • (1989) J. Chem. Soc., Perkin Trans. 2 , vol.2 , pp. 1355-1375
    • Abraham, M.H.1    Duce, P.P.2    Prior, D.V.3
  • 203
    • 79960228477 scopus 로고    scopus 로고
    • Quantitatively interpreted enhanced inhibition of cytochrome P450s by heteroaromatic rings containing nitrogen
    • Leach, A. G. and Kidley, N. J. (2011) Quantitatively interpreted enhanced inhibition of cytochrome P450s by heteroaromatic rings containing nitrogen J. Chem. Inf. Model. 51, 1048-1063 10.1021/ci2000506
    • (2011) J. Chem. Inf. Model. , vol.51 , pp. 1048-1063
    • Leach, A.G.1    Kidley, N.J.2
  • 204
    • 80053601542 scopus 로고    scopus 로고
    • Are pyridazines privileged structures?
    • Wermuth, C. G. (2011) Are pyridazines privileged structures? MedChemComm 2, 935-941 10.1039/c1md00074h
    • (2011) MedChemComm , vol.2 , pp. 935-941
    • Wermuth, C.G.1
  • 205
    • 84863856481 scopus 로고    scopus 로고
    • Mitigating heterocycle metabolism in drug discovery
    • St. Jean, D. J., Jr. and Fotsch, C. (2012) Mitigating heterocycle metabolism in drug discovery J. Med. Chem. 55, 6002-6020 10.1021/jm300343m
    • (2012) J. Med. Chem. , vol.55 , pp. 6002-6020
    • St. Jean, D.J.1    Fotsch, C.2
  • 206
    • 84920194283 scopus 로고    scopus 로고
    • Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals
    • Vitaku, E., Smith, D. T., and Njardarson, J. T. (2014) Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals J. Med. Chem. 57, 10257-10274 10.1021/jm501100b
    • (2014) J. Med. Chem. , vol.57 , pp. 10257-10274
    • Vitaku, E.1    Smith, D.T.2    Njardarson, J.T.3
  • 207
    • 84858853853 scopus 로고    scopus 로고
    • Idiosyncratic reactions and metabolism of sulfur-containing drugs
    • Zuniga, F. I., Loi, D., Ling, K. H., and Tang-Liu, D. D. (2012) Idiosyncratic reactions and metabolism of sulfur-containing drugs Expert Opin. Drug Metab. Toxicol. 8, 467-485 10.1517/17425255.2012.668528
    • (2012) Expert Opin. Drug Metab. Toxicol. , vol.8 , pp. 467-485
    • Zuniga, F.I.1    Loi, D.2    Ling, K.H.3    Tang-Liu, D.D.4
  • 208
  • 213
    • 84856204276 scopus 로고    scopus 로고
    • Drug discovery: Chemical beauty contest
    • Leeson, P. (2012) Drug discovery: chemical beauty contest Nature 481, 455-456 10.1038/481455a
    • (2012) Nature , vol.481 , pp. 455-456
    • Leeson, P.1
  • 214
    • 48049086591 scopus 로고    scopus 로고
    • Lessons learnt from assembling screening libraries for drug discovery for neglected diseases
    • Brenk, R., Schipani, A., James, D., Krasowski, A., Gilbert, I. H., Frearson, J., and Wyatt, P. G. (2008) Lessons learnt from assembling screening libraries for drug discovery for neglected diseases ChemMedChem 3, 435-444 10.1002/cmdc.200700139
    • (2008) ChemMedChem , vol.3 , pp. 435-444
    • Brenk, R.1    Schipani, A.2    James, D.3    Krasowski, A.4    Gilbert, I.H.5    Frearson, J.6    Wyatt, P.G.7
  • 215
    • 0037369622 scopus 로고    scopus 로고
    • Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: Comparison with fluoxetine and quinidine
    • Bertelsen, K. M., Venkatakrishnan, K., Von Moltke, L. L., Obach, R. S., and Greenblatt, D. J. (2003) Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine Drug Metab. Dispos. 31, 289-293 10.1124/dmd.31.3.289
    • (2003) Drug Metab. Dispos. , vol.31 , pp. 289-293
    • Bertelsen, K.M.1    Venkatakrishnan, K.2    Von Moltke, L.L.3    Obach, R.S.4    Greenblatt, D.J.5
  • 216
    • 18844426008 scopus 로고    scopus 로고
    • In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: Prediction of nonstationary pharmacokinetics and drug interaction magnitude
    • Venkatakrishnan, K. and Obach, R. S. (2005) In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude Drug Metab. Dispos. 33, 845-852 10.1124/dmd.105.004077
    • (2005) Drug Metab. Dispos. , vol.33 , pp. 845-852
    • Venkatakrishnan, K.1    Obach, R.S.2
  • 220
    • 1942435958 scopus 로고    scopus 로고
    • Leflunomide for the treatment of rheumatoid arthritis in clinical practice: Incidence and severity of hepatotoxicity
    • van Roon, E. N., Jansen, T. L., Houtman, N. M., Spoelstra, P., and Brouwers, J. R. (2004) Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity Drug Saf. 27, 345-352 10.2165/00002018-200427050-00006
    • (2004) Drug Saf. , vol.27 , pp. 345-352
    • Van Roon, E.N.1    Jansen, T.L.2    Houtman, N.M.3    Spoelstra, P.4    Brouwers, J.R.5
  • 221
    • 70449722872 scopus 로고    scopus 로고
    • Benefit-risk assessment of leflunomide: An appraisal of leflunomide in rheumatoid arthritis 10 years after licensing
    • Alcorn, N., Saunders, S., and Madhok, R. (2009) Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing Drug Saf. 32, 1123-1134 10.2165/11316650-000000000-00000
    • (2009) Drug Saf. , vol.32 , pp. 1123-1134
    • Alcorn, N.1    Saunders, S.2    Madhok, R.3
  • 222
    • 78649922972 scopus 로고    scopus 로고
    • Drug-induced valvulopathy: An update
    • Elangbam, C. S. (2010) Drug-induced valvulopathy: an update Toxicol. Pathol. 38, 837-848 10.1177/0192623310378027
    • (2010) Toxicol. Pathol. , vol.38 , pp. 837-848
    • Elangbam, C.S.1
  • 223
    • 1542357574 scopus 로고    scopus 로고
    • The pharmacokinetics of pergolide in Parkinson's disease
    • Blin, O. (2003) The pharmacokinetics of pergolide in Parkinson's disease Curr. Opin. Neurol. 16 (Suppl. 1) S9-12 10.1097/00019052-200312001-00003
    • (2003) Curr. Opin. Neurol. , vol.16 , pp. S9-S12
    • Blin, O.1
  • 225
    • 84938495908 scopus 로고    scopus 로고
    • Molecular property design: Does everyone get it?
    • Leeson, P. D. and Young, R. J. (2015) Molecular property design: does everyone get it? ACS Med. Chem. Lett. 6, 722-725 10.1021/acsmedchemlett.5b00157
    • (2015) ACS Med. Chem. Lett. , vol.6 , pp. 722-725
    • Leeson, P.D.1    Young, R.J.2
  • 226
    • 34250745809 scopus 로고    scopus 로고
    • Compensating enthalpic and entropic changes hinder binding affinity optimization
    • Lafont, V., Armstrong, A. A., Ohtaka, H., Kiso, Y., Amzel, L. M., and Freire, E. (2007) Compensating enthalpic and entropic changes hinder binding affinity optimization Chem. Biol. Drug Des. 69, 413-422 10.1111/j.1747-0285.2007.00519.x
    • (2007) Chem. Biol. Drug Des. , vol.69 , pp. 413-422
    • Lafont, V.1    Armstrong, A.A.2    Ohtaka, H.3    Kiso, Y.4    Amzel, L.M.5    Freire, E.6
  • 227
    • 77957229353 scopus 로고    scopus 로고
    • Thermodynamics guided lead discovery and optimization
    • Ferenczy, G. G. and Keserũ, G. M. (2010) Thermodynamics guided lead discovery and optimization Drug Discovery Today 15, 919-932 10.1016/j.drudis.2010.08.013
    • (2010) Drug Discovery Today , vol.15 , pp. 919-932
    • Ferenczy, G.G.1    Keserũ, G.M.2
  • 228
    • 0041854716 scopus 로고    scopus 로고
    • Understanding binding affinity: A combined isothermal titration calorimetry/molecular dynamics study of the binding of a series of hydrophobically modified benzamidinium chloride inhibitors to trypsin
    • Talhout, R., Villa, A., Mark, A. E., and Engberts, J. B. (2003) Understanding binding affinity: a combined isothermal titration calorimetry/molecular dynamics study of the binding of a series of hydrophobically modified benzamidinium chloride inhibitors to trypsin J. Am. Chem. Soc. 125, 10570-10579 10.1021/ja034676g
    • (2003) J. Am. Chem. Soc. , vol.125 , pp. 10570-10579
    • Talhout, R.1    Villa, A.2    Mark, A.E.3    Engberts, J.B.4
  • 229
    • 84964628143 scopus 로고    scopus 로고
    • ACS Webinar, Jan 29, 2015
    • Leeson, P. D. (2015) Designing Better Drug Candidates, ACS Webinar, Jan 29, 2015, available at http://www.acs.org/content/dam/acsorg/events/business-entrepreneurship/Slides/2015-01-29-dd1.pdf.
    • (2015) Designing Better Drug Candidates
    • Leeson, P.D.1
  • 230
    • 27744548649 scopus 로고    scopus 로고
    • The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS
    • Wood, A. and Armour, D. (2005) The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS Prog. Med. Chem. 43, 239-271 10.1016/S0079-6468(05)43007-6
    • (2005) Prog. Med. Chem. , vol.43 , pp. 239-271
    • Wood, A.1    Armour, D.2
  • 233
    • 84892615575 scopus 로고    scopus 로고
    • Update on the discovery and development of cholesteryl ester transfer protein inhibitors for reducing residual cardiovascular risk
    • Mantlo, N. B. and Escribano, A. (2014) Update on the discovery and development of cholesteryl ester transfer protein inhibitors for reducing residual cardiovascular risk J. Med. Chem. 57, 1-17 10.1021/jm400574e
    • (2014) J. Med. Chem. , vol.57 , pp. 1-17
    • Mantlo, N.B.1    Escribano, A.2
  • 238
    • 84921525633 scopus 로고    scopus 로고
    • Recent advances in the development of acetyl-CoA carboxylase (ACC) inhibitors for the treatment of metabolic disease
    • Bourbeau, M. P. and Bartberger, M. D. (2015) Recent advances in the development of acetyl-CoA carboxylase (ACC) inhibitors for the treatment of metabolic disease J. Med. Chem. 58, 525-536 10.1021/jm500695e
    • (2015) J. Med. Chem. , vol.58 , pp. 525-536
    • Bourbeau, M.P.1    Bartberger, M.D.2
  • 239
    • 0023780482 scopus 로고
    • Free Wilson analysis. Theory, applications and its relationship to Hansch analysis
    • Kubinyi, H. (1988) Free Wilson analysis. Theory, applications and its relationship to Hansch analysis Quant. Struct.-Act. Relat. 7, 121-133 10.1002/qsar.19880070303
    • (1988) Quant. Struct.-Act. Relat. , vol.7 , pp. 121-133
    • Kubinyi, H.1
  • 244
    • 77950922576 scopus 로고    scopus 로고
    • Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1 infected patients
    • Fätkenheuer, G., Staszewski, S., Plettenburg, A., Hackman, F., Layton, G., McFadyen, L., Davis, J., and Jenkins, T. M. (2009) Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1 infected patients AIDS 23, 2115-2122 10.1097/QAD.0b013e32832fef5b
    • (2009) AIDS , vol.23 , pp. 2115-2122
    • Fätkenheuer, G.1    Staszewski, S.2    Plettenburg, A.3    Hackman, F.4    Layton, G.5    McFadyen, L.6    Davis, J.7    Jenkins, T.M.8
  • 249
    • 84922752398 scopus 로고    scopus 로고
    • Aza follow-ups to BI 207524, a thumb pocket 1 HCV NS5B polymerase inhibitor. Part 1: Mitigating the genotoxic liability of an aniline metabolite
    • Beaulieu, P. L., Bolger, G., Duplessis, M., Gagnon, A., Garneau, M., Stammers, T., Kukolj, G., and Duan, J. (2015) Aza follow-ups to BI 207524, a thumb pocket 1 HCV NS5B polymerase inhibitor. Part 1: mitigating the genotoxic liability of an aniline metabolite Bioorg. Med. Chem. Lett. 25, 1135-1139 10.1016/j.bmcl.2014.12.028
    • (2015) Bioorg. Med. Chem. Lett. , vol.25 , pp. 1135-1139
    • Beaulieu, P.L.1    Bolger, G.2    Duplessis, M.3    Gagnon, A.4    Garneau, M.5    Stammers, T.6    Kukolj, G.7    Duan, J.8
  • 250
    • 84922733798 scopus 로고    scopus 로고
    • Multi-parameter optimization of aza-follow-ups to BI 207524, a thumb pocket 1 HCV NS5B polymerase inhibitor. Part 2: Impact of lipophilicity on promiscuity and in vivo toxicity
    • Beaulieu, P. L., Bolger, G., Deon, D., Duplessis, M., Fazal, G., Gagnon, A., Garneau, M., LaPlante, S., Stammers, T., Kukolj, G., and Duan, J. (2015) Multi-parameter optimization of aza-follow-ups to BI 207524, a thumb pocket 1 HCV NS5B polymerase inhibitor. Part 2: Impact of lipophilicity on promiscuity and in vivo toxicity Bioorg. Med. Chem. Lett. 25, 1140-1145 10.1016/j.bmcl.2014.12.078
    • (2015) Bioorg. Med. Chem. Lett. , vol.25 , pp. 1140-1145
    • Beaulieu, P.L.1    Bolger, G.2    Deon, D.3    Duplessis, M.4    Fazal, G.5    Gagnon, A.6    Garneau, M.7    LaPlante, S.8    Stammers, T.9    Kukolj, G.10    Duan, J.11
  • 251
    • 84884230698 scopus 로고    scopus 로고
    • Evaluating the differences in cycloalkyl ether metabolism using the design parameter "lipophilic metabolism efficiency" (LipMetE) and a matched molecular pairs analysis
    • Stepan, A. F., Kauffman, G. W., Keefer, C. E., Verhoest, P. R., and Edwards, M. (2013) Evaluating the differences in cycloalkyl ether metabolism using the design parameter "lipophilic metabolism efficiency" (LipMetE) and a matched molecular pairs analysis J. Med. Chem. 56, 6985-6990 10.1021/jm4008642
    • (2013) J. Med. Chem. , vol.56 , pp. 6985-6990
    • Stepan, A.F.1    Kauffman, G.W.2    Keefer, C.E.3    Verhoest, P.R.4    Edwards, M.5
  • 253
    • 84878845602 scopus 로고    scopus 로고
    • The development of CNS-active LRRK2 inhibitors using property-directed optimization
    • Kavanagh, M. E., Doddareddy, M. R., and Kassiou, M. (2013) The development of CNS-active LRRK2 inhibitors using property-directed optimization Bioorg. Med. Chem. Lett. 23, 3690-3696 10.1016/j.bmcl.2013.04.086
    • (2013) Bioorg. Med. Chem. Lett. , vol.23 , pp. 3690-3696
    • Kavanagh, M.E.1    Doddareddy, M.R.2    Kassiou, M.3
  • 259
    • 84897471004 scopus 로고    scopus 로고
    • Design and synthesis of high affinity inhibitors of Plasmodium falciparum and Plasmodium vivax N -myristoyltransferases directed by ligand efficiency dependent lipophilicity (LELP)
    • Rackham, M. D., Brannigan, J. A., Rangachari, K., Meister, S., Wilkinson, A. J., Holder, A. A., Leatherbarrow, R. J., and Tate, E. W. (2014) Design and synthesis of high affinity inhibitors of Plasmodium falciparum and Plasmodium vivax N -myristoyltransferases directed by ligand efficiency dependent lipophilicity (LELP) J. Med. Chem. 57, 2773-2788 10.1021/jm500066b
    • (2014) J. Med. Chem. , vol.57 , pp. 2773-2788
    • Rackham, M.D.1    Brannigan, J.A.2    Rangachari, K.3    Meister, S.4    Wilkinson, A.J.5    Holder, A.A.6    Leatherbarrow, R.J.7    Tate, E.W.8
  • 260
    • 84865518339 scopus 로고    scopus 로고
    • A matched molecular pair analysis of in vitro human microsomal metabolic stability measurements for heterocyclic replacements of di-substituted benzene containing compounds - Identification of those isosteres more likely to have beneficial effects
    • Dossetter, A. G., Douglas, A., and O'Donnell, C. (2012) A matched molecular pair analysis of in vitro human microsomal metabolic stability measurements for heterocyclic replacements of di-substituted benzene containing compounds-identification of those isosteres more likely to have beneficial effects MedChemComm 3, 1164-1169 10.1039/c2md20155k
    • (2012) MedChemComm , vol.3 , pp. 1164-1169
    • Dossetter, A.G.1    Douglas, A.2    O'Donnell, C.3
  • 261
    • 0030014882 scopus 로고    scopus 로고
    • (S)-(+)-2-(3′-carboxybicyclo[1.1.1]pentyl)-glycine, a structurally new group I metabotropic glutamate receptor antagonist
    • Pellicciari, R., Raimondo, M., Marinozzi, M., Natalini, B., Costantino, G., and Thomsen, C. (1996) (S)-(+)-2-(3′-carboxybicyclo[1.1.1]pentyl)-glycine, a structurally new group I metabotropic glutamate receptor antagonist J. Med. Chem. 39, 2874-2876 10.1021/jm960254o
    • (1996) J. Med. Chem. , vol.39 , pp. 2874-2876
    • Pellicciari, R.1    Raimondo, M.2    Marinozzi, M.3    Natalini, B.4    Costantino, G.5    Thomsen, C.6
  • 262
    • 0032537619 scopus 로고    scopus 로고
    • Synthesis and preliminary evaluation of (S)-2-(40-carboxycubyl)glycine, a new selective mGluR1 antagonist
    • Pellicciari, R., Costantino, G., Giovagnoni, E., Mattoli, L., Brabet, I., and Pin, J.-P. (1998) Synthesis and preliminary evaluation of (S)-2-(40-carboxycubyl)glycine, a new selective mGluR1 antagonist Bioorg. Med. Chem. Lett. 8, 1569-1574 10.1016/S0960-894X(98)00265-0
    • (1998) Bioorg. Med. Chem. Lett. , vol.8 , pp. 1569-1574
    • Pellicciari, R.1    Costantino, G.2    Giovagnoni, E.3    Mattoli, L.4    Brabet, I.5    Pin, J.-P.6
  • 263
    • 0035080723 scopus 로고    scopus 로고
    • Synthesis and biological evaluation of 2-(3′-(1 H -tetrazol-5-yl)bicyclo[1.1.1]pent-1-yl)glycine (S-TBPG), a novel mGlu1 receptor antagonist
    • Costantino, G., Maltoni, K., Marinozzi, M., Camaioni, E., Prezeau, L., Pin, J.-P., and Pellicciari, R. (2001) Synthesis and biological evaluation of 2-(3′-(1 H -tetrazol-5-yl)bicyclo[1.1.1]pent-1-yl)glycine (S-TBPG), a novel mGlu1 receptor antagonist Bioorg. Med. Chem. 9, 221-227 10.1016/S0968-0896(00)00270-4
    • (2001) Bioorg. Med. Chem. , vol.9 , pp. 221-227
    • Costantino, G.1    Maltoni, K.2    Marinozzi, M.3    Camaioni, E.4    Prezeau, L.5    Pin, J.-P.6    Pellicciari, R.7
  • 266
    • 8944253773 scopus 로고    scopus 로고
    • Regiochemical variations in reactions of methylcubane with tert -butoxyl radical, cytochrome P-450 enzymes, and a methane monooxygenase system
    • Choi, S.-Y., Eaton, P. E., Hollenberg, P. F., Liu, K. E., Lippard, S. J., Newcomb, M., Putt, D. A., and Upadhyaya, S. P. (1996) Regiochemical variations in reactions of methylcubane with tert -butoxyl radical, cytochrome P-450 enzymes, and a methane monooxygenase system J. Am. Chem. Soc. 118, 6547-6555 10.1021/ja952226l
    • (1996) J. Am. Chem. Soc. , vol.118 , pp. 6547-6555
    • Choi, S.-Y.1    Eaton, P.E.2    Hollenberg, P.F.3    Liu, K.E.4    Lippard, S.J.5    Newcomb, M.6    Putt, D.A.7    Upadhyaya, S.P.8
  • 267
    • 33748298066 scopus 로고
    • Cubanes: Starting materials for the chemistry of the 1990s and the new century
    • Eaton, P. E. (1992) Cubanes: starting materials for the chemistry of the 1990s and the new century Angew. Chem., Int. Ed. Engl. 31, 1421-1436 10.1002/anie.199214211
    • (1992) Angew. Chem., Int. Ed. Engl. , vol.31 , pp. 1421-1436
    • Eaton, P.E.1
  • 269
    • 47149111206 scopus 로고    scopus 로고
    • Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: Discovery of novel, highly potent inhibitors of Factor Xa
    • Qiao, J. X., Cheney, D. L., Alexander, R. S., Smallwood, A. M., King, S. R., He, K., Rendina, A. R., Luettgen, J. M., Knabb, R. M., Wexler, R. R., and Lam, P. Y. (2008) Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: discovery of novel, highly potent inhibitors of Factor Xa Bioorg. Med. Chem. Lett. 18, 4118-4123 10.1016/j.bmcl.2008.05.095
    • (2008) Bioorg. Med. Chem. Lett. , vol.18 , pp. 4118-4123
    • Qiao, J.X.1    Cheney, D.L.2    Alexander, R.S.3    Smallwood, A.M.4    King, S.R.5    He, K.6    Rendina, A.R.7    Luettgen, J.M.8    Knabb, R.M.9    Wexler, R.R.10    Lam, P.Y.11
  • 271
    • 72249121632 scopus 로고    scopus 로고
    • Triazole oxytocin antagonists: Identification of an aryloxyazetidine replacement for a biaryl substituent
    • Brown, A., Brown, T. B., Calabrese, A., Ellis, D., Puhalo, N., Ralph, M., and Watson, L. (2010) Triazole oxytocin antagonists: identification of an aryloxyazetidine replacement for a biaryl substituent Bioorg. Med. Chem. Lett. 20, 516-520 10.1016/j.bmcl.2009.11.097
    • (2010) Bioorg. Med. Chem. Lett. , vol.20 , pp. 516-520
    • Brown, A.1    Brown, T.B.2    Calabrese, A.3    Ellis, D.4    Puhalo, N.5    Ralph, M.6    Watson, L.7
  • 282
    • 84925664415 scopus 로고    scopus 로고
    • ATM and ATR as therapeutic targets in cancer
    • Weber, A. M. and Ryan, A. J. (2015) ATM and ATR as therapeutic targets in cancer Pharmacol. Ther. 149, 124-138 10.1016/j.pharmthera.2014.12.001
    • (2015) Pharmacol. Ther. , vol.149 , pp. 124-138
    • Weber, A.M.1    Ryan, A.J.2
  • 284
    • 52649083344 scopus 로고    scopus 로고
    • Discovery of ABT-263, a Bcl-family protein inhibitor: Observations on targeting a large protein-protein interaction
    • Wendt, M. D. (2008) Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein-protein interaction Expert Opin. Drug Discovery 3, 1123-1143 10.1517/17460441.3.9.1123
    • (2008) Expert Opin. Drug Discovery , vol.3 , pp. 1123-1143
    • Wendt, M.D.1
  • 287
    • 84891804059 scopus 로고    scopus 로고
    • The role of lymphatic transport on the systemic bioavailability of the Bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199
    • Choo, E. F., Boggs, J., Zhu, C., Lubach, J. W., Catron, N. D., Jenkins, G., Souers, A. J., and Voorman, R. (2014) The role of lymphatic transport on the systemic bioavailability of the Bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199 Drug Metab. Dispos. 42, 207-212 10.1124/dmd.113.055053
    • (2014) Drug Metab. Dispos. , vol.42 , pp. 207-212
    • Choo, E.F.1    Boggs, J.2    Zhu, C.3    Lubach, J.W.4    Catron, N.D.5    Jenkins, G.6    Souers, A.J.7    Voorman, R.8
  • 288
    • 84863845342 scopus 로고    scopus 로고
    • Lipophilic isosteres of a π-π stacking interaction: New inhibitors of the Bcl-2-Bak protein-protein interaction
    • Yusuff, N., Doré, M., Joud, C., Visser, M., Springer, C., Xie, X., Herlihy, K., Porter, D., and Touré, B. B. (2012) Lipophilic isosteres of a π-π stacking interaction: new inhibitors of the Bcl-2-Bak protein-protein interaction ACS Med. Chem. Lett. 3, 579-583 10.1021/ml300095a
    • (2012) ACS Med. Chem. Lett. , vol.3 , pp. 579-583
    • Yusuff, N.1    Doré, M.2    Joud, C.3    Visser, M.4    Springer, C.5    Xie, X.6    Herlihy, K.7    Porter, D.8    Touré, B.B.9
  • 292
  • 295
    • 84938680591 scopus 로고    scopus 로고
    • Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183
    • Marchetti, S., Pluim, D., Beijnen, J. H., Mazzanti, R., van Tellingen, O., and Schellens, J. H. (2014) Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183 Invest. New Drugs 32, 1083-1095 10.1007/s10637-014-0143-0
    • (2014) Invest. New Drugs , vol.32 , pp. 1083-1095
    • Marchetti, S.1    Pluim, D.2    Beijnen, J.H.3    Mazzanti, R.4    Van Tellingen, O.5    Schellens, J.H.6
  • 297
    • 26844487304 scopus 로고    scopus 로고
    • Synthesis and biological evaluation of methoxylated analogs of the newer generation taxoids IDN5109 and IDN5390
    • Barboni, L., Ballini, R., Giarlo, G., Appendino, G., Fontana, G., and Bombardelli, E. (2005) Synthesis and biological evaluation of methoxylated analogs of the newer generation taxoids IDN5109 and IDN5390 Bioorg. Med. Chem. Lett. 15, 5182-5186 10.1016/j.bmcl.2005.08.066
    • (2005) Bioorg. Med. Chem. Lett. , vol.15 , pp. 5182-5186
    • Barboni, L.1    Ballini, R.2    Giarlo, G.3    Appendino, G.4    Fontana, G.5    Bombardelli, E.6
  • 300
    • 1842843197 scopus 로고    scopus 로고
    • Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023
    • Minderman, H., Brooks, T. A., O'Loughlin, K. L., Ojima, I., Bernacki, R. J., and Baer, M. R. (2004) Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023 Cancer Chemother. Pharmacol. 53, 363-369 10.1007/s00280-003-0745-2
    • (2004) Cancer Chemother. Pharmacol. , vol.53 , pp. 363-369
    • Minderman, H.1    Brooks, T.A.2    O'Loughlin, K.L.3    Ojima, I.4    Bernacki, R.J.5    Baer, M.R.6
  • 302
    • 33751570159 scopus 로고    scopus 로고
    • Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral C-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors
    • Frapolli, R., Marangon, E., Zaffaroni, M., Colombo, T., Falcioni, C., Bagnati, R., Simone, M., D'Incalci, M., Manzotti, C., Fontana, G., Morazzoni, P., and Zucchetti, M. (2006) Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral C-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors Drug Metab. Dispos. 34, 2028-2035 10.1124/dmd.106.012153
    • (2006) Drug Metab. Dispos. , vol.34 , pp. 2028-2035
    • Frapolli, R.1    Marangon, E.2    Zaffaroni, M.3    Colombo, T.4    Falcioni, C.5    Bagnati, R.6    Simone, M.7    D'Incalci, M.8    Manzotti, C.9    Fontana, G.10    Morazzoni, P.11    Zucchetti, M.12
  • 305
    • 16544390219 scopus 로고    scopus 로고
    • Absorption, distribution, and excretion of DJ-927, a novel orally effective taxane, in mice, dogs, and monkeys
    • Ono, C., Takao, A., and Atsumi, R. (2004) Absorption, distribution, and excretion of DJ-927, a novel orally effective taxane, in mice, dogs, and monkeys Biol. Pharm. Bull. 27, 345-351 10.1248/bpb.27.345
    • (2004) Biol. Pharm. Bull. , vol.27 , pp. 345-351
    • Ono, C.1    Takao, A.2    Atsumi, R.3
  • 306
    • 0038419962 scopus 로고    scopus 로고
    • DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo
    • Shionoya, M., Jimbo, T., Kitagawa, M., Soga, T., and Tohgo, A. (2003) DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo Cancer Sci. 94, 459-466 10.1111/j.1349-7006.2003.tb01465.x
    • (2003) Cancer Sci. , vol.94 , pp. 459-466
    • Shionoya, M.1    Jimbo, T.2    Kitagawa, M.3    Soga, T.4    Tohgo, A.5
  • 307
    • 82455162574 scopus 로고    scopus 로고
    • Tesetaxel, a new oral taxane, in combination with capecitabine: A phase I, dose-escalation study in patients with advanced solid tumors
    • Saif, M. W., Sarantopoulos, J., Patnaik, A., Tolcher, A. W., Takimoto, C., and Beeram, M. (2011) Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors Cancer Chemother. Pharmacol. 68, 1565-1573 10.1007/s00280-011-1639-3
    • (2011) Cancer Chemother. Pharmacol. , vol.68 , pp. 1565-1573
    • Saif, M.W.1    Sarantopoulos, J.2    Patnaik, A.3    Tolcher, A.W.4    Takimoto, C.5    Beeram, M.6
  • 308
  • 315
    • 84964589478 scopus 로고    scopus 로고
    • HCV NS3/4a Protease Inhibitors: Simeprevir (TMC-435350), Vaniprevir (MK-7009) and MK-5172
    • (Desai M. and Meanwell N.A., Eds.) Chapter 7, RSC Drug Discovery Series No. 32, RSC Publishing, Cambridge, England
    • McCauley, J. A., Rudd, M. T., and Liverton, N. J. (2013) HCV NS3/4a Protease Inhibitors: Simeprevir (TMC-435350), Vaniprevir (MK-7009) and MK-5172, Successful Strategies for the Discovery of Antiviral Drugs (Desai, M. and Meanwell, N. A., Eds.) Chapter 7, pp 189-247, RSC Drug Discovery Series No. 32, RSC Publishing, Cambridge, England.
    • (2013) Successful Strategies for the Discovery of Antiviral Drugs , pp. 189-247
    • McCauley, J.A.1    Rudd, M.T.2    Liverton, N.J.3
  • 317
    • 84948586560 scopus 로고    scopus 로고
    • Asunaprevir: A review of preclinical and clinical pharmacokinetics and drug-drug interactions
    • Eley, T., Garimella, T., Li, W., and Bertz, R. J. (2015) Asunaprevir: a review of preclinical and clinical pharmacokinetics and drug-drug interactions Clin. Pharmacokinet. 54, 1205-1222 10.1007/s40262-015-0299-6
    • (2015) Clin. Pharmacokinet. , vol.54 , pp. 1205-1222
    • Eley, T.1    Garimella, T.2    Li, W.3    Bertz, R.J.4
  • 318
    • 84883178669 scopus 로고    scopus 로고
    • Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporin
    • Brennan, B. J., Moreira, S. A., Morcos, P. N., Navarro, M. T., Asthappan, J., Goelzer, P., Weigl, P., and Smith, P. F. (2013) Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporin Clin. Pharmacokinet. 52, 805-813 10.1007/s40262-013-0077-2
    • (2013) Clin. Pharmacokinet. , vol.52 , pp. 805-813
    • Brennan, B.J.1    Moreira, S.A.2    Morcos, P.N.3    Navarro, M.T.4    Asthappan, J.5    Goelzer, P.6    Weigl, P.7    Smith, P.F.8
  • 319
    • 56749177102 scopus 로고    scopus 로고
    • Permeability evaluation of peptidic HCV protease inhibitors in Caco-2 cells-correlation with in vivo absorption predicted in humans
    • Li, C., Liu, T., Broske, L., Brisson, J. M., Uss, A. S., Njoroge, F. G., Morrison, R. A., and Cheng, K. C. (2008) Permeability evaluation of peptidic HCV protease inhibitors in Caco-2 cells-correlation with in vivo absorption predicted in humans Biochem. Pharmacol. 76, 1757-1764 10.1016/j.bcp.2008.09.005
    • (2008) Biochem. Pharmacol. , vol.76 , pp. 1757-1764
    • Li, C.1    Liu, T.2    Broske, L.3    Brisson, J.M.4    Uss, A.S.5    Njoroge, F.G.6    Morrison, R.A.7    Cheng, K.C.8
  • 320
    • 70449533153 scopus 로고    scopus 로고
    • Hepatitis C virus NS3 protease inhibitors: Large, flexible molecules of peptide origin show satisfactory permeability across Caco-2 cells
    • Bergström, C. A., Bolin, S., Artursson, P., Rönn, R., and Sandström, A. (2009) Hepatitis C virus NS3 protease inhibitors: large, flexible molecules of peptide origin show satisfactory permeability across Caco-2 cells Eur. J. Pharm. Sci. 38, 556-563 10.1016/j.ejps.2009.10.004
    • (2009) Eur. J. Pharm. Sci. , vol.38 , pp. 556-563
    • Bergström, C.A.1    Bolin, S.2    Artursson, P.3    Rönn, R.4    Sandström, A.5
  • 325
    • 84901277262 scopus 로고    scopus 로고
    • Preclinical pharmacokinetics and in vitro metabolism of BMS-605339: A novel HCV NS3 protease inhibitor
    • Jenkins, S., Scola, P., McPhee, F., Knipe, J., Gesenberg, C., Sinz, M., Arora, V., Pilcher, G., and Santone, K. (2014) Preclinical pharmacokinetics and in vitro metabolism of BMS-605339: a novel HCV NS3 protease inhibitor J. Pharm. Sci. 103, 1891-1902 10.1002/jps.23959
    • (2014) J. Pharm. Sci. , vol.103 , pp. 1891-1902
    • Jenkins, S.1    Scola, P.2    McPhee, F.3    Knipe, J.4    Gesenberg, C.5    Sinz, M.6    Arora, V.7    Pilcher, G.8    Santone, K.9
  • 327
    • 33847381100 scopus 로고    scopus 로고
    • A decade of fragment-based drug design: Strategic advances and lessons learned
    • Hajduk, P. J. and Greer, J. (2007) A decade of fragment-based drug design: strategic advances and lessons learned Nat. Rev. Drug Discovery 6, 211-219 10.1038/nrd2220
    • (2007) Nat. Rev. Drug Discovery , vol.6 , pp. 211-219
    • Hajduk, P.J.1    Greer, J.2
  • 328
    • 67649341990 scopus 로고    scopus 로고
    • From fragment to clinical candidate - A historical perspective
    • Chessari, G. and Woodhead, A. J. (2009) From fragment to clinical candidate-a historical perspective Drug Discovery Today 14, 668-675 10.1016/j.drudis.2009.04.007
    • (2009) Drug Discovery Today , vol.14 , pp. 668-675
    • Chessari, G.1    Woodhead, A.J.2
  • 329
    • 84860511479 scopus 로고    scopus 로고
    • Experiences in fragment-based drug discovery
    • Murray, C. W., Verdonk, M. L., and Rees, D. C. (2012) Experiences in fragment-based drug discovery Trends Pharmacol. Sci. 33, 224-232 10.1016/j.tips.2012.02.006
    • (2012) Trends Pharmacol. Sci. , vol.33 , pp. 224-232
    • Murray, C.W.1    Verdonk, M.L.2    Rees, D.C.3
  • 330
    • 84862869077 scopus 로고    scopus 로고
    • Fragment-based approaches in drug discovery and chemical biology
    • Scott, D. E., Coyne, A. G., Hudson, S. A., and Abell, C. (2012) Fragment-based approaches in drug discovery and chemical biology Biochemistry 51, 4990-5003 10.1021/bi3005126
    • (2012) Biochemistry , vol.51 , pp. 4990-5003
    • Scott, D.E.1    Coyne, A.G.2    Hudson, S.A.3    Abell, C.4
  • 332
    • 84872038006 scopus 로고    scopus 로고
    • Inflation of correlation in the pursuit of drug-likeness
    • Kenny, P. W. and Montanari, C. A. (2013) Inflation of correlation in the pursuit of drug-likeness J. Comput.-Aided Mol. Des. 27, 1-13 10.1007/s10822-012-9631-5
    • (2013) J. Comput.-Aided Mol. Des. , vol.27 , pp. 1-13
    • Kenny, P.W.1    Montanari, C.A.2
  • 333
    • 84856405594 scopus 로고    scopus 로고
    • Going further than Lipinski's rule in drug design
    • Walters, W. P. (2012) Going further than Lipinski's rule in drug design Expert Opin. Drug Discovery 7, 99-107 10.1517/17460441.2012.648612
    • (2012) Expert Opin. Drug Discovery , vol.7 , pp. 99-107
    • Walters, W.P.1
  • 334
    • 84899101946 scopus 로고    scopus 로고
    • Curing chronic hepatitis C - The arc of a medical triumph
    • Chung, R. T. and Baumert, T. F. (2014) Curing chronic hepatitis C - the arc of a medical triumph N. Engl. J. Med. 370, 1576-1578 10.1056/NEJMp1400986
    • (2014) N. Engl. J. Med. , vol.370 , pp. 1576-1578
    • Chung, R.T.1    Baumert, T.F.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.